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ZUSAMMENFASSUNG  I 
ZUSAMMENFASSUNG 
Der Cholesterin-Stoffwechsel ist sehr streng auf zellulärer Ebene reguliert und ist essentiell 
für das Zellwachstum. Zelluläre Ungleichgewichte des Cholesterin- und Fettsäure-
Stoffwechsels führen zu pathologischen Prozessen, einschließlich Atherosklerose und 
Metabolisches Syndrom. MicroRNAs (miRNAs), eine Klasse nicht-kodierender RNAs, 
wurden als kritische Regulatoren der Genexpression identifiziert und entfalten ihre Wirkung 
vorwiegend auf posttranskriptioneller Ebene. Aktuelle Arbeiten aus der Gruppe um 
Fernández-Hernando und andere haben gezeigt, dass hsa-miR-33a und hsa-miR-33b, 
miRNAs die in den Intronsequenzen der Gene für die Sterol-regulatorischen Element-
Bindungsproteine (SREBP-2 und SREBP -1) lokalisiert sind, den Cholesterin-Stoffwechsel 
im Einklang mit ihren Wirtsgenen regulieren. Gleichermaßen inhibiert miR-33 
Schlüsselenzyme in der Regulation der Fettsäureoxidation, einschließlich Carnitin O-
octanoyltransferase (CROT), Carnitinpalmitoyltransferase 1A (CPT1A), Hydroxyacyl-CoA 
Thiolase-Dehydrogenase/3-ketoacyl-CoA / Enoyl-CoA Hydratase (HADHB), Sirtuin 6 (SIRT6) 
und AMP-aktivierte Proteinkinase (AMPK) α, genauso wie das Insulin-Rezeptor-Substrat 2 
(IRS2), eine wesentliche Komponente des Insulin-Signalwegs in der Leber.  
Diese Studie zeigt, dass hsa-miR-33 Familienmitglieder nicht nur Gene in Cholesterin- und 
Fettsäure-Stoffwechsel sowie Insulin-Signalwege regulieren, sondern zusätzlich die 
Expression von Genen des Zellzyklus und der Zellproliferation modulieren. miR-33 inhibiert 
die Expression der Cyclin-abhängigen Kinase 6 (CDK6) und Cyclin-D1 (CCND1), wodurch 
sowohol die Zellproliferation als auch die Zellzyklusprogression verringert wird. Die 
Überexpression von miR-33 induziert einen signifikanten G1 Zellzyklusarrest. Durch eine 
Inhibierung der miR-33 Expression mittels 2'fluoro / Methoxyethyl-modifizierte (2'F / MOE-
modifiziert) Phosphorothioat-Backbone Antisense-Oligonukleotiden, wird die 
Leberregeneration nach partieller Hepatektomie (PH) in Mäusen verbessert, was auf eine 
wichtige Rolle für miR-33 in der Regulation der Hepatozytenproliferation während der 
Leberregeneration hinweist. 
ZUSAMMENFASSUNG   II 
 
Zusammengefasst zeigen diese Daten, dass miR-33 Signalwege reguliert, die drei der 
Risikofaktoren des Metabolischen Syndroms, nämlich HDL, Triglyzeride und Insulin-
Signaling steuern, und legen nahe, dass Inhibitoren von miR-33 bei der Behandlung dieses 
zunehmenden gesundheitlichen Problems nützlich sein können. Ferner könnte der 
Srebf/miR-33 Locus kooperieren, um Zellproliferation und Zellzyklusprogression zu 
regulieren, und könnte somit auch relevant für die menschliche Leberregeneration sein. 
 
Schlagwörter: CDK6, Cyclin D1, miR-33, Zellzyklus, microRNA 
ABSTRACT   III 
ABSTRACT 
Cholesterol metabolism is tightly regulated at the cellular level and is essential for cellular growth. 
Cellular imbalances of cholesterol and fatty acid metabolism lead to pathological processes, 
including atherosclerosis and metabolic syndrome. MicroRNAs (miRNAs), a class of noncoding 
RNAs, have emerged as critical regulators of gene expression acting predominantly at 
posttranscriptional level. Recent work from Fernández-Hernando´s group and others has shown 
that hsa-miR-33a and hsa-miR-33b, miRNAs located within intronic sequences of the sterol 
regulatory element-binding protein (SREBP-2 and SREBP-1) genes, respectively, regulate 
cholesterol metabolism in concert with their host genes. Similarly, miR-33 targets key enzymes 
involved in the regulation of fatty acid oxidation including carnitine O-octanoyltransferase (CROT), 
carnitine palmitoyltransferase 1A (CPT1A), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (HADHB), sirtuin 6 (SIRT6) and AMP-activated protein kinase 
(AMPK)α, likewise, the insulin receptor substrate 2 (IRS2), an essential component of the insulin-
signaling pathway in the liver. This study shows that hsa-miR-33 family members not only 
regulate genes involved in cholesterol and fatty acid metabolism and insulin signaling, but in 
addition modulate the expression of genes involved in cell cycle regulation and cell proliferation. 
Thus, miR-33 inhibited the expression of the cyclin-dependent kinase 6 (CDK6) and cyclin D1 
(CCND1), thereby reducing cell proliferation and cell cycle progression. Over-expression of miR-
33 induced a significant G1 cell cycle arrest and most importantly, inhibition of miR-33 expression 
using 2’fluoro/methoxyethyl-modified (2’F/MOE-modified) phosphorothioate backbone antisense 
oligonucleotides improved liver regeneration after partial hepatectomy (PH) in mice, suggesting 
an important role for miR-33 in regulating hepatocyte proliferation during liver regeneration. 
Altogether, these data establish that miR-33 regulates pathways controlling three of the risk 
factors of metabolic syndrome, namely levels of HDL, triglycerides and insulin signaling, and 
suggest that inhibitors of miR-33 may be useful in the treatment of this growing health concern. 
Furthermore, Srebf/miR-33 locus may co-operate to regulate cell proliferation, cell cycle 
progression and may also be relevant to human liver regeneration. 
Keywords: CDK6, Cyclin D1, miR-33, cell cycle, microRNA 
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1 INTRODUCTION 
1.1 Regulation of cholesterol metabolism 
 
Cholesterol is an essential component of mammalian membranes and a precursor in 
metabolic pathways, including steroid hormones and bile acids [1-4]. Cells require 
cholesterol to modulate membrane fluidity and permeability, for proliferation, cell growth and 
division, as well as during embryonic development [1-4]. Cholesterol homeostasis thus needs 
to be tightly regulated, and dysregulation of lipid metabolism is a primary perturbation 
associated with the development of many diseases such as atherosclerosis, metabolic 
syndrome and type II diabetes [5, 6]. 
Animal cells synthesize cholesterol from acetyl coenzyme A (acetyl-CoA) in a highly 
regulated enzymatic pathway [7], including more than 20 enzymatic reaction steps [8]. In 
addition, cells obtain cholesterol from the circulation via apolipoprotein B-containing 
lipoproteins, such as low density lipoprotein (LDL) [1, 9]. LDL particles are internalized by the 
peripheral cells via the LDL receptor (LDLr), receptor-mediated endocytosis, and are 
hydrolyzed to free cholesterol in the lysosomes [1, 9]. Intracellular cholesterol levels are 
tightly controlled by feedback mechanisms that operate at both, transcriptional and 
posttranscriptional levels [10, 11]. When intracellular levels of cholesterol are low, the 
endoplasmatic reticulum (ER)-bound sterol regulatory element-binding proteins (SREBPs) 
coordinate the transcription of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCoAR), a rate-limiting enzyme of the biosynthetic pathway, and almost all down-stream 
enzymes of the mevalonate (MVA) pathway [12]. SREBPs also activate the transcription of 
the LDLr, which leads to an increase in cellular cholesterol uptake [10]. In contrast, when 
cells accumulate excess sterols, the activity of HMGCoAR declines more than 90% and the 
cell surface expression of LDLr decreases [10]. The SREBP family of basic-helix-loop-helix-
leucine zipper (bHLH-LZ) transcription factors consists of SREBP1a, SREBP1c and SREBP-
2 proteins encoded by two unique genes, Srebf-1 and Srebf-2. The SREBPs differ in their 
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tissue-specific expression, the target genes selectivity and the relative potencies of their 
transactivation domains. SREBP2 preferentially controls the synthesis and uptake of 
cholesterol, through the regulation of both LDLr and HMGCoAR, whereas SREBP1a and 
SREBP1c regulate genes involved in the synthesis of fatty acids and, as more recently 
found, cell cycle regulation [11, 13-15]. When intracellular levels of cholesterol are high, the 
liver X receptor (LXr), a nuclear hormone receptor, also contributes to the cholesterol 
homeostasis by activating the transcription of genes involved in cholesterol efflux, including 
the ATP-binding cassette transporters, ABCA1 and ABCG1 [16] (Figure 1). These 
transporters promote cellular cholesterol efflux to high-density lipoprotein (HDL) and its 
associated apolipoprotein, ApoA-1, a crucial step in the initiation of reverse cholesterol 
transport to the liver for excretion into bile [17, 18]. Because HDL levels correlate inversely 
with the susceptibility to atherosclerosis, there is an increasing interest in studying the 
regulation, mechanism of action, and suitability of ABCA1 as a target to increase HDL levels 
for the treatment and prevention of atherosclerosis [19]. 
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Figure 1. Regulation of cellular cholesterol homeostasis. Animal cells synthesize cholesterol from acetyl-CoA. 
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In addition, cells obtain cholesterol from the circulation in the form of apolipoprotein B-containing lipoproteins, 
particularly LDL. The circulating LDL particles carrying cholesterol and cholesterol esters are internalized through 
LDLr and transported to sorting endosomes. LDL particles are subsequently transported to late endosomes and 
lysosomes, whereas LDL receptors are recycled to the plasma membrane. Free cholesterol egress from 
endosomes and lysosomes in a process mediated by Niemann-Pick type C 1 and 2 proteins (NPC1 and NPC2). 
Under low intracellular cholesterol concentration, the SCAP-SREBP complex moves to the Golgi where the 
SREBP is processed to its nuclear form. The nuclear SREBP turns on genes involved in cholesterol biosynthesis 
(e.g. HMGCoAR) and cholesterol uptake (LDLr). Conversely, in response to cellular cholesterol excess, the 
oxysterols generated bind and activate the liver X receptor (LXr), which heterodimerize with retinoic X receptor 
(RXR) and activate the expression of ATP transporters (ABCA1 and ABCG1). ABCA1 and ABCG1 promote 
cholesterol efflux via apoA1 and HDL, respectively, and help to maintain intracellular cholesterol homeostasis 
(Modified from Moore et al. [20])    
 
 
1.2 Regulation of the cell cycle 
 
To ensure proper growth and maintenance of an organism, mammalian cells exhibit a 
rigorously controlled cycle of growth and cell division. Cell division leads, via mitosis and 
cytokinesis, to two equal daughter cells. Proliferation describes cell growth, accumulation of 
cell properties and subsequent cell division. There are four main parts of the cell cycle, the 
mitosis (M phase), and the three interphases, first gap (G1), synthesis (S) and second gap 
(G2) [21-23]. Immediately after cell division RNA and proteins start to accumulate. This 
period of the cell cycle between the end of mitosis and the subsequent onset of DNA 
synthesis is termed G1. Usually this gap takes 12 to 15 hours. Variances in cycle duration 
are mostly due to differences in entering and exiting G1 phase, and to an optional break in 
quiescence state (G0); or even entering the differentiation modus [21-23]. This is mostly 
influenced by growth factors in the cell’s surroundings. In sufficient concentrations these 
extracellular signals will encourage a cell to continue progressing the cell cycle, or their 
absence will trigger the cell to proceed into G0. This critical decision point in the cell cycle, 
several hours before the end of G1, is termed restriction point (R point) [21-23]. This also 
resembles the point of no return, and once the cell has passed this critical point, it will 
proceed with the G1/S phase transition. The following S phase, during which the DNA 
synthesis occurs, typically requires 6 to 8 hours to reach completion. The G2 phase takes 3 
to 5 hours. Finally, the M phase extends approximately one hour, and includes four distinct 
subphases: prophase, metaphase, anaphase, and telophase. Mitosis finishes with 
cytokinesis: the division of the cytoplasm [21-23]. There are several DNA damage control 
points in G1 and G2 phases and the spindle-assembly checkpoint in the M phase [23]. 
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The time a cell needs to progress through the cell cycle is greatly depending on cell type and 
on circumjacent conditions. The indicated lengths of each phase are commonly observed in 
cultured cells. Hence, actively proliferating lymphocytes may double in only 5 hours, and 
some cells in the early embryo may do so even more rapidly [24-27]. 
Controlled cell cycle progression is driven mainly by protein complexes composed of two 
subunits: a cyclin and a corresponding cyclin-dependent kinase (CDK). CDKs are small 
serine/threonine kinases that require association with a cyclin subunit for their activation. 
Cyclin/CDKs catalyze the phosphorylation of specific target substrates. These 
phosphorylation events are transient and reversible. When the cyclin/CDK complex 
disassembles, the phosphorylated substrates are rapidly dephosphorylated by protein 
phosphatases [28, 29]. Active cyclin/CDK complexes lead to the activation of transcription 
factors, which induce the transcription of the next set of cyclins and CDKs. Consequently, 
there is a rapid turnover and a tight regulation, which involves controlled transcription and 
degradation of cyclins. Regulation also involves the activation and inhibition of the CDKs via 
phosphorylation/dephosphorylation events, and the control of inhibitory proteins that 
associate with cyclin/CDK complexes [30-32] (Figure 2). During G1 phase, the D-type 
cyclins (CCND1, CCND2, and CCND3) bind and activate CDK4 and CDK6 [33-35]. Both 
CDKs have similar enzymatic activities. In late G1 after the R point, CDK2 primarily interacts 
with E-type cyclins (CCNE1 and CCNE2) to phosphorylate specific substrates required for 
the initiation of DNA replication and centrosome duplication in the S phase [36-41]. When the 
cells enter the S phase, the A-type cyclins (CCNA1 and CCNA2) substitute CCNE1 and 
CCNE2 as partners of CDK2 to promote progression through the S phase. Cyclin A 
phosphorylates proteins involved in DNA replication, such as CDC6 [42-44]. At the end of the 
S phase, the A-type cyclins now associate with CDK1 (CDC2) [44-46]. Moving further into G2 
phase, CDK1 largely associates to the mitotic B-type cyclins (CCNB1 and CCNB2). During 
G2/M transition, cyclin A activity is needed for the initiation of the prophase [47]. At the 
mitotic exit, the cyclin/CDK complexes are required for chromosomal alignment and 
progression to the anaphase [48-50]. At the onset of the M phase, the B-type cyclin/CDK1 
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complex triggers many of the essential procedures that constitute mitosis and end in 
cytokinesis [51, 52]. The levels of CDKs slightly vary during cell cycle, only the cyclins 
fluctuate in a cell cycle dependent manner, thereby their name. For example, cyclin B 
strongly increases at the onset of mitosis to associate with CDK1. At the end of the M phase, 
cyclin B levels drop due to rapid degradation and is undetectable at the beginning of the next 
cell cycle. The only exceptions in fluctuating levels are the D-type cyclins, which are 
constantly expressed [53, 54]. 
 
Figure 2. Mammalian cell-cycle regulation. According to classical model of cell cycle regulation Cdk4, Cdk6, 
Cdk2 and Cdk1 complex with phase-specific cyclins at different stages of cell cycle to coordinate initiation and 
progression of cell cycle. (Adapted from Satyanarayana et al. [55]) 
 
1.3 Mechanisms of action and biogenesis of miRNAs 
 
In addition to the classical transcriptional regulators, members of a class of non-coding 
RNAs, termed microRNAs (miRNAs), have lately been identified as important post-
transcriptional regulators of gene expression [56-59]. miRNAs are small (22 nucleotides), 
single-stranded, non-coding RNAs, which were first discovered in the nematode 
Caenorhabditis elegans [60, 61]. They are encoded in the genomes of almost all eukaryotes 
and some viruses [59]. miRNAs typically control the expression of their target genes by 
primarily acting as sequence specific inhibitors of the corresponding messenger RNA 
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(mRNA). This inhibitory effect can occur by either transcript destabilization, translational 
inhibition, or both [58, 59, 62]. Bioinformatics predictions and experimental approaches 
indicate that a single miRNA could target more than one hundred mRNAs [63]. Indeed, 
human miRNAs are predicted to control the activity of more than 60% of all protein-coding 
genes [59, 63, 64]. miRNAs have now been implicated in the control of a wide range of 
biological functions including development, differentiation, metabolism, growth, proliferation 
and apoptosis [65-70]. 
miRNAs are located through the genome within exonic and intronic portions of protein-coding 
genes, as well as in intergenic regions [56-59]. As illustrated in Figure 3, the production of 
functional 22 nucleotides mature miRNA involves multiple processing steps. Most animal 
miRNAs are transcribed in the nucleus by RNA polymerase II as stem-loop long primary 
transcripts (pri-miRNA) [71]. The pri-miRNAs are usually thousands of nucleotides long and 
contain local hairpin structures. Following transcription, they are processed sequentially in 
the nucleus and cytoplasm by a complex of RNase-III endonucleases: the so called Drosha 
and Dicer. Specifically, Drosha processes the pri-miRNA transcript to a 70-100 nucleotide 
stem-loop precursor RNA (pre-miRNA), which is then delivered to the cytoplasm by Exportin 
5, where it is subsequently cleaved by Dicer to produce a ~22 nucleotides miRNA:miRNA* 
duplex (canonical pathway) [56, 58, 59]. However, a subset of intronic miRNAs called 
“miRtrons” can circumvent the Drosha pathway and are made by splicing and debranching of 
short hairpin introns [72-74]. The Dicer cleavage can alternatively be conducted by Ago2, an 
Argonaute protein that is part of the complex that aligns the miRNA and the mRNA [75-77]. 
Once in the cytoplasm, one of the duplex strand (miRNA or miRNA*) is preferentially 
incorporated into the RNA-induced silencing complex (RISC) in association with an Ago 
family member [56, 58, 59]. Within the RISC-Ago-entity, the miRNA guides the complex to its 
RNA target, thereby mediating its repression. In animals, miRNAs control gene expression 
by binding to the 3´UTR of their target genes through Watson-Crick base pairing between the 
target and the 5’-end of the miRNAs: representing the “seed sequence” (nucleotides 2-8) [56, 
58, 59]. However, recent studies suggest that miRNAs might also repress mRNA targets by 
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binding to other regions including 5´UTR or protein-coding exons [78-81]. This interaction 
typically leads to translational repression of target mRNAs by either transcript destabilization, 
translational inhibition, or both [56, 58, 59]. 
Identifying functionally important miRNA target genes is crucial for understanding the impact 
of specific miRNAs on cellular function. This has been challenging, because miRNAs usually 
have imperfect complementarity with their targets [58]. In mammals, the most consistent 
requirement of miRNA-target interaction, although not always essential, is a contiguous and 
perfect base pairing of the miRNA at the nucleotides 2-8, the “seed sequence”. In many 
cases, the seed seems to determine this recognition. However, in other cases, additional 
determinants are required, such as reasonable complementarity to the miRNA 3´half to 
stabilize the interaction (nucleotides 13-16). In addition, some other features of the 3´UTR 
sequences surrounding the target site, such as AU-rich sequences, positioned within the 
3´UTR at least 50 nucleotides from the stop codon and away from the center of long UTRs, 
could boost miRNA efficacy [58]. The existence of multiple public miRNA target prediction 
algorithms has greatly facilitated the rapid identification of miRNA target genes, which 
however, still require validation.   
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Figure 3. miRNA biogenesis and function. miRNAs are transcribed in the nucleus into primary transcripts (pri-
miRNAs). They are transcribed from independent miRNA genes, from polycistronic transcripts or from introns of 
protein-coding genes. Pri-miRNAs are then processed in two steps in the nucleus and cytoplasm, catalyzed by 
the RNase III type endonuclease Drosha and Dicer, respectively. These enzymes function in complexes with 
dsRNA-binding domains proteins, DGCR8 and TRBP for Drosha and Dicer, respectively. In the canonical 
pathway (illustrated here) Drosha-DGCR8 processes the transcript to a stem-loop-structured precursor (pre-
miRNA). A subset of miRNAs, called miRtrons, also derived from introns, is processed into pre-miRNAs by the 
spliceosome and the debranching enzyme. Both canonical miRNAs and miRtrons are exported to the cytoplasm 
via Exportin 5, where they are further processed by Dicer-TRBP to yield ≈ 20-bp miRNA duplexes. The typical 
Dicer cleavage product features 5′ phosphate groups and two-nucleotide overhangs at the 3′ ends. One strand is 
selected to function as mature miRNA and loaded into the RISC, while the partner miRNA* strand is preferentially 
degraded. In contrast, the precursor of miR-451 is recognized directly by Ago2. The unusual structure of the 
precursor (short stem, miRNA sequence spans the loop) promotes binding and cleavage by Ago2 after the 30th 
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nucleotide. Therefore, miR-451 is produced independently of Dicer. The miRNA is further matured by so far 
unknown mechanisms. The mature miRNA produced by these two mechanisms leads to translational repression 
or mRNA degradation. The key components of the RISC are components of the Argonaute family (Ago 1–4). 
Animal miRNAs usually show only partial complementarity to the target mRNA promoting translational repression 
(initiation and post initiation steps) or deadenylation coupled to exonucleolytic degradation of target mRNA. 
mRNAs repressed by deadenylation or at the translation-initiation step are moved to P-bodies for either 
degradation or storage (Modified from Suarez et al.[70]). 
 
1.4 miRNAs and cell cycle  
 
Deregulated miRNA expression can result from impaired miRNA processing, copy number 
alterations of miRNA encoding loci, or the methylation of miRNA promoter regions. Many 
miRNAs are located in chromosomal regions subjected to abnormalities in human cancer. 
Tumor suppressors maintain cell cycle checkpoint integrity and regulate apoptotic responses, 
so copy number loss at these loci can enhance tumorigenesis and contribute to a poor 
clinical outcome. Deletion of certain miRNA loci in distinct tumor types, and correlation of 
miRNA deletion with poor clinical prognosis has led to the prediction that miRNAs may act as 
tumor suppressors [67]. Croce and colleagues provided some of the first evidence that 
specific miRNA loci may act as human tumor suppressors [82]. For years, it has been known 
that deletions at chromosome 13q14 are common in chronic lymphocyte leukemia (CLL). 
However, despite intensive efforts, no loss of protein encoding transcript could be linked to 
these deletions. More recently, Calin et al. showed that the chromosomal region deleted in 
CLL contains the miRNA cluster encoding miR-15a and miR-16-1. Reduced expression of 
miR-15a and miR-16 was observed in 75% of CLL cases harboring this deletion. Subsequent 
studies showed that over-expression of the miR-15a/miR-16-1 cluster in a leukemia-derived 
cell line repressed levels of the anti-apoptotic protein BCL2 and induced apoptosis [83]. 
Another recent study suggested that miR-16 family miRNAs may directly regulate cell cycle 
progression and proliferation by controlling the G1 checkpoint. Over-expression of miR-16 
family microRNAs led to induction of G0/G1 arrest in cultured human tumor cells [31]. Many 
miR-16 targets were identified, whose repression could induce G0/G1 accumulation. One of 
these targets was CDK6 [84], which is activated when it binds D-type cyclins in early G1 
phase, as described before. CDK6/cyclin D complexes participate in the sequential 
hyperphosphorylation of retinoblastoma protein (RB) by CDK4/6 and CDK2 to repress RB 
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mediated inhibition of the transcription factor E2F, which positively regulates G1 to S phase 
progression.  
In several neuroblastoma (NB) cell lines overexpression of miR-184 induced cell cycle arrest 
at G1, followed by apoptosis [85]. On the other hand, miR-34a loss has also been associated 
with NB. Comparative genomic hybridization demonstrated that miR-34a is located in the 
minimal region of 1p loss in NB tumors with 1p deletions and deletion of chromosome 1p was 
connected to poor NB prognosis [86]. In addition, expression of miR-34a was reduced in NB 
cell lines and advanced stage primary NB tumors relative to normal tissue [86]. Contrary, 
overexpression of miR-34a in several NB cell lines induced growth arrest followed by 
apoptosis [86]. E2F was identified as a putative miR-34a target, and both the activity of a 
luciferase-based reporter construct containing the E2F miR-34 target site in its 3' UTR and 
levels of endogenous E2F protein were reduced by miR-34a overexpression [86]. These data 
were interpreted to indicate that miR-34a exhibits the characteristics of a tumor suppressor in 
NB. The miR-34 family comprises three highly conserved miRNAs: miR-34a, miR-34b and 
miR-34c. Recently, miR-34 family members were shown to be directly regulated by the tumor 
suppressor p53 [87-90]. Overexpression of each miR-34 family member caused cell cycle 
arrest at G1, downregulation of a significant number of cell cycle related genes [87] and 
overlapped significantly with genes regulated by DNA damage [86]. These observations 
suggest that the miR-34 family plays a role in the p53-mediated DNA damage checkpoint by 
downregulating cell cycle genes and eliciting G1 arrest. He et al. validated several of the 
downregulated genes as direct targets by showing miR-34 regulation of reporters engineered 
to contain the 3' UTRs of the respective targets. These target genes included CDK4, CCNE2, 
and a receptor tyrosine kinase (MET) [87].  
In addition, Liu et al. identified miR-137 as a potential regulator of Cdc42 expression, one of 
the best characterized members of the Rho GTPase family upregulated in several human 
tumors. Expression of miR-137 in colorectal cancer cell lines inversely correlated, both at the 
mRNA and the protein level, with Cdc42 expression and the transfection with the miRNA 
could significantly suppress Cdc42 3’UTR luciferase-reporter activity. Finally, the 
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downregulation of Cdc42 by miR-137 inhibited proliferation inducing G1 cell cycle arrest and 
blocked the invasion of colorectal cancer cells, whereas anti-miR-137 expression induced the 
opposite effect [91].     
In summary, accumulating evidence suggests that other miRNAs may also directly regulate 
cell cycle checkpoints and cellular proliferation. 
 
1.5 Cholesterol and cell cycle 
 
The requirement of cholesterol for cell growth and cell division of mammalian cells has been 
known for many years [2, 3, 92], but whether this is just a consequence of its use for 
membrane formation or whether it also plays a regulatory role during cell cycle has not yet 
been clarified. Cholesterol is also required for cell cycle progression, and its deficiency leads 
to cell cycle arrest in G2/M [93]. Moreover, other non-mevalonate derivates are essential for 
the G1-S transition, thus confirming the relationship between the cholesterol synthesis 
pathway and cell cycle progression [94, 95]. SREBPs have also been implicated in the 
regulation of cell cycle [96]. Bengoechea-Alonso et al. have demonstrated that siRNA-
mediated silencing of SREBP1 in human HeLa, U2OS and MCF-7 cells lead to an 
accumulation of cells in late G1 phase, prior to the G1/S transition [96]. By contrast, 
SREBP1-a overexpression, activated the transcription of p21WAF1/CIP1, a universal cyclin-
dependent kinase inhibitor, leading to cell growth inhibition and G1 cell cycle arrest [97]. In 
addition to p21WAF1/CIP1, SREBP-1a activation also increased the accumulation of other 
CDK inhibitors, including p27 and p16, leading to reduced CDK2 and CDK4 activities and 
hypophosphorylation of RB protein [98]. Interestingly, SREBP-1a transgenic mice exhibited 
impaired liver regeneration after partial hepatectomy [98]. 
 
1.6 miR-33 is a key regulator of cholesterol metabolism 
 
Most recently, several independent groups including Fernández-Hernando´s laboratory, have 
identified miR-33a and miR-33b, intronic miRNAs located within the Srebf-2 and Srebf-1 
genes, respectively [99-101]. The same metabolic pathways that activate the expression of 
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Srebf-2 and Srebf-1 lead to an increased expression of miR-33a and miR-33b respectively, 
suggesting a coregulation between the host genes and the corresponding miRNAs. 
Moreover, Horie et al. recently cloned fragments of the mouse Srebf-2 gene including miR- 
33a (Exon 16-17) and showed that miR-33a is coordinately expressed when Srebf-2 is 
activated [102]. miR-33a target genes were found to be involved in cholesterol trafficking, 
including ABCA1, ABCG1, and Niemann-Pick type C1 protein (NPC1) [99-101, 103]. 
Interestingly, ABCA1, a transporter responsible for the movement of cholesterol out of the 
cell, was among the top predicted target genes for miR-33a. miR-33a overexpression 
strongly repressed ABCA1 expression and decreased cellular cholesterol efflux to ApoA-1. 
Conversely, antagonism of endogenous miR-33 upregulated ABCA1 expression in vitro and 
in vivo, and promoted cholesterol efflux to ApoA-1, further confirming the physiological 
effects of miR-33 [99-101, 103]. Similar results were observed in mouse peritoneal 
macrophages isolated from miR-33 null mice [102]. miR-33 also targets ABCG1, but only in 
rodents [101]. Accordingly, miR-33 repressed cholesterol efflux to mature HDL in mouse cells 
but not in human cells [101]. Together, these findings establish a reciprocal pathway in 
which, during sterol-poor conditions, miR-33a is coincidentally generated with SREBP-2 and 
increases cellular cholesterol levels by downregulating ABCA1 and ABCG1 and thus, limits 
cholesterol efflux (Figure 4). 
As mentioned above, ABCA1 plays a key role in regulating HDL biogenesis in vivo. 
Remarkably, antagonists of miR-33 in vivo using locked nucleic acid (LNA)-modified 
oligonucleotides, lentivirus and adenovirus significantly increased the expression of ABCA1 
in the liver and the plasma HDL levels. Similar results were observed in miR-33 knockout 
mice [102]. Low levels of HDL correlated with increased cardiovascular disease risk, thereby 
the regulation, mechanism of action, and suitability of ABCA1 are a target to increase HDL 
levels for the treatment and prevention of atherosclerosis [102]. To assess whether or not 
anti-miR-33 therapy increases reverse cholesterol transport and promotes regression of 
atherosclerosis, Rayner and colleagues treated LDLr-/- mice with established atherosclerotic 
plaques with anti-miR-33 oligonucleotides. Interestingly, mice treated with anti-miR-33 
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oligonucleotides presented smaller plaques with increased fibrous caps and reduced necrotic 
cores, phenotypic characteristics of stable plaques and less severe atherosclerosis [104]. 
 
1.7 miR-33 coordinates genes regulating fatty acid and glucose metabolism 
 
In addition to the cholesterol transporter genes, ABCA1, ABCG1 and NPC1, two independent 
studies have recently shown that miR-33a and miR-33b binding sites are highly conserved in 
the in the 3´UTR of genes involved in fatty acid oxidation including, Cpt1a, Crot, Hadhb, and 
Ampk [103]. Gerin´s and Fernández-Hernando´s groups have demonstrated that miR-33 
decreased the expression of CPT1a, CROT, and HADHB at the mRNA and the protein level 
[101,103]. Furthermore, overexpression of miR-33a and miR-33b reduced fatty acid oxidation 
and lead to the accumulation of triglycerides in human Huh7 hepatic cells and in the fat body 
of miR-33 transgenic flies [105]. Moreover, miR-33 was shown to inhibit the expression of 
AMPK, a cellular energy sensor that coordinates hepatic lipid metabolism at the 
transcriptional and post-transcriptional level. In the liver, activation of AMPK promoted fatty 
acid oxidation, while inhibiting cholesterol and triglyceride synthesis [106]. Taken these 
results together, miR-33a and miR-33b appear to be fundamental modulators of lipid 
metabolism by limiting cellular cholesterol efflux and fatty acid degradation upon SREBP 
induction (Figure 4).  
Previous work from Fernández-Hernando´s laboratory also revealed an interesting role for 
miR-33 in glucose metabolism, as miR-33 overexpression inhibited IRS2, an essential 
docking molecule that mediates the effects of insulin [105]. Consistent with these findings, 
miR-33 overexpression reduced insulin-induced 2-deoxyglucose (2-DOG) uptake in hepatic 
cells [105]. In addition, miR-33 inhibited SIRT6, which has been involved in regulating fatty 
acid and glucose homeostasis. Indeed, hepatic-specific disruption of SIRT6 in mice resulted 
in the formation of “fatty liver” because of enhanced glucolysis and triglyceride synthesis 
[105]. More work needs to be done to elucidate the function of miR-33 concerning glucose 
metabolism, but unpublished data strongly suggest an essential role of miRNA-33 as a 
modulator of lipid, cholesterol and carbohydrate metabolism. 
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Figure 4. Maintenance of cholesterol, fatty acid and carbohydrate metabolism by sterol regulatory 
element binding proteins (SREBPs) and miR-33a and -b in hepatocytes. In hepatocytes, when intracellular 
cholesterol levels are low, SREBP-2 is sequentially cleaved in the Golgi by two membrane-bound proteases, site-
1 protease (S1P) and site-2 protease (S2P). The N-terminal fragment is released and translocates to the nucleus, 
where it acts as a transcription factor to regulate genes containing a sterol response element (SRE), including 
Srebp-2. Conversely, the Srebp-1c promoter contains a liver X receptor (LXR) binding site that activates SREBP-
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1c transcription in the presence of LXR agonists or insulin. Activation of SREBP-2 or SREBP-1 results in the 
cotranscription of miR-33a and miR-33b, respectively. These miRNAs simultaneously inhibit the expression of 
genes involved in cholesterol transport (ABCA1, ABCG1, and NPC1) and fatty acid oxidation (CROT, CPT1a, 
HADHB, and AMPK), thereby decreasing reverse cholesterol transport and reducing fatty acid β-oxidation. miR-
33a and miR-33b also contribute to the regulation of glucose metabolism, by targeting IRS2 and SIRT6.  
HDL, high density lipoprotein; ABCA1, ATPbinding cassette transporter A1; ABCG1, ATP-binding cassette 
transporter G1; FC, free cholesterol; CE, cholesteryl ester; NPC1, Niemann-Pick disease, type C1; LE, late 
endosome; ER, endoplasmic reticulum; SCAP, SREBP cleavage activating protein; RXR, retinoid X receptor; 
LXRE, liver X receptor element; CPT1a, carnitine palmitoyltransferase 1A ; CROT, carnitine 
Ooctanoyltransferase; HADHB, hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit; IRS2, insulin receptor substrate 2; SIRT6,sirtuin 6 (Modified from Ramírez et 
al. [107]). 
 
1.8 A role for miR-33 in cell cycle regulation 
  
Recently, Herrera-Merchán et al. reported that in super-p53 mice (sp53), which carry one 
extra gene dose of p53, the miR-33 is downregulated in hematopoietic stem cells (HSCs) 
and highly expressed in multipotent progenitors. Transplantation assays of miR-33-
transduced sp53 HSC resulted in a significant acquisition of repopulating capacity and a 
decrease of recipients’ survival. Moreover, high levels of miR-33 repressed the endogenous 
level of p53 protein in murine embryonic fibroblasts (MeFs), lead both to neoplastic 
transformation and anchorage independent growth of MeFs, and provoked a decrease of 
apoptotic response using tumor-derived cell lines. Accordingly, it was demonstrated that 
miR-33-mediated downregulation of p53 is dependent on the binding of miR-33 to two 
conserved motifs in the 3'UTR of p53 [108].  
Likewise, a group in Marburg also newly established miR-33a as a miRNA with potential 
tumor suppressor activity, acting through inhibition of the proto-oncogene serine/threonine-
protein kinase (Pim)-1[109]. A screen for miRNA expression in K562 lymphoma, LS174T 
colon carcinoma and several other cell lines revealed generally low endogenous miR-33a 
levels relative to other miRNAs. After transfection of K562 and LS174T cells with miR-33a a 
substantially reduced Pim-1 levels were observed. Seed mutagenesis of the Pim-1 3′UTR 
region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient 
Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic 
[109]. The persistence of this effect was comparable to that of a small interfering RNA-
mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, the 
potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a 
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replacement therapy through delivery of miRNA mimics as a novel therapeutic strategy, was 
demonstrated [108-109]. 
Similarly to Srebp/miR-33 locus, the α-mysion heavy chain (alphaMHG) gene, in addition to 
encoding a major cardiac contractile protein, regulates cardiac growth and gene expression 
in response to stress and hormonal signaling through miR-208 [110]. Altogether, the 
observations strongly suggest that intronic miRNAs work in conjunction with host genes to 
regulate similar cellular processes.  
 
1.9 Aim of the project 
 
Previous experiments in our laboratory clearly showed miR-33a to be cotranscribed with its 
host gene Srebf-2 like many intronic miRNAs. Among other genes regulated by miR-33a are: 
ABCA1, which is involved in cholesterol export and efflux to Apo-A1; ABCG1, which is 
reducing cholesterol efflux to nascent HDL; and NPC1, which is regulating endolysosomal 
cholesterol transport. This regulatory function of miR-33a ensures that the cell is protected 
under low sterol conditions from additional sterol loss. Thus, miR-33 appears to regulate both 
HDL biogenesis in the liver and cellular cholesterol efflux.  
In addition to this role in maintaining cholesterol homeostasis, the group also showed that 
miR-33a and miR-33b also regulate fatty acid metabolism and insulin signaling. Putative 
binding sites for miR-33 in the 3′UTR of CROT, CPT1a, HADHB, AMPKα and IRS2 were 
identified and it was demonstrated that miR-33a and miR-33b specifically inhibit the 
expression of these genes. The physiological relevance of this targeting is revealed by miR-
33 overexpression in hepatic cells, were both fatty acid oxidation and insulin signaling are 
reduced. Furthermore, inhibition of endogenous miR-33 increased the expression of CROT, 
CPT1a, HADHB, AMPKα, and IRS2 and upregulated fatty acid oxidation and insulin 
signaling. Together, these data suggest that feedback loops involving SREBPs, miR-33a and 
miR-33b balance cholesterol metabolism, fatty acid oxidation, and insulin signaling; three of 
the major risk factors of metabolic syndrome. 
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Since SREBPs regulate cellular proliferation and cell cycle progression, in the current study, 
we tested the role of miR-33 in regulating these cellular functions. We identified putative 
binding-sites for miR-33 in the 3´UTR of cyclin-dependent kinases (CDK6, CDK8, and 
CDK19), CCND1 and CCND2, p53, Pten, Myc and mitogen-activated protein kinases 
(Map3k1, Map3k7, Mapk1, Mapk3, Mapk6, Mapk10 and Mapk14). The potential targets of 
miR-33 were validated analyzing the mRNA and the protein levels by in vitro overexpression 
and inhibition of the miR-33 in HeLa, Huh7 and A549 cell lines. Moreover, the binding sites in 
the 3´UTR of two predicted genes were confirmed by luciferase assay. Further, the role of 
miR-33 during proliferation and cell cycle progression was studied in vivo in a liver 
regeneration model after partial hepatectomy in mice. Finally, the conditional miR-33 
knockout mouse model was designed and generated. This tool enables us to knockout miR-
33 in a controlled and specific manner by using inducible mouse models, in order to further 
investigate the biological role of miR-33 in different tissues.  
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2 MATERIAL AND METHODS  
  
Standard protocols for various techniques in molecular biology were mainly performed 
according to Molecular Cloning (3rd Edition, Sambrook & Russel, Cold Spring Harbor 
Laboratory Press, 2001). 
 
2.1 Cloning 
 
Overview tables of all constructs and primers are placed in section 2.8.2 and 2.8.3.  
 
2.1.1 Bacterial E. coli strains  
 
Chemically competent DH5α (Invitrogen, California, USA) were used for the propagation of 
standard vectors and routine subcloning. Chemically competent and electrocompetent Top10 
(Invitrogen, USA) and chemically competent Stbl2 (Invitrogen, USA) were used to amplify 
special constructs bigger than 5000bp. Chemically XL10-Gold ultracompetent cells 
(Stratagene, USA) were used to amplify the point mutated constructs. Bacteria were 
propagated in standard LB medium (MP Biomedicals, USA) or LB agar (MP Biomedicals, 
USA) at 37°C in a shaking incubator (Thermo Scientific Heraeus Series 6000 Incubators, 
Thermo Scientific, USA) unless noted.  
 
2.1.2 Polymerase chain reaction (PCR)  
 
PCR reactions for cloning approaches were performed with Phusion Hot Start High-Fidelity 
DNA polymerase (Finnzymes, Colorado, USA), since this enzyme possesses proofreading 
exonuclease activity. If 3’-A overhangs were necessary (e.g. for TOPO-TA cloning) Taq DNA 
polymerase (Biolabs, UK) was used. Analytical PCR reactions were conducted with standard 
Taq DNA Polymerase (Eppendorf, Germany). Standard reactions were performed after an 
initial denaturation (95°C, 5 min) for 30-35 cycles of denaturation (95°C, 30 sec), annealing 
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(55-65°C, 30 sec), and extension (72 °C, 30-180 sec) followed by a final extension step in a 
MJ Research PTC-200 thermo cycler (MJ Research, USA). 
2.1.3 Agarose gel electrophoresis  
 
DNA molecules were separated by gel electrophoresis in standard electrophoresis grade 0,5-
2% agarose gels (Invitrogen, USA). If gel extraction of the DNA fragment was required for 
cloning purposes, gels were prepared with TopVision Agarose (Fermentas, Canada). The 
electrophoresis was performed in a custom system (Bächler Feintech, Germany) at 80 V for 
30-60 min in TBE-Buffer (45 mM Tris-borate, 1 mM EDTA, pH 8.3) in case of analytical gels 
and TAE-Buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) for cloning approaches. Ethidium 
bromide (0.5μg/ml) was included in the buffer and gel to visualize DNA bands by UV light 
(Syngene, USA). 
 
2.1.4 Plasmid isolation 
 
For small scale plasmid isolations (max 1μg), 3ml LB medium including 100 μg/ml ampicillin 
or kanamycin antibiotics, depending on the plasmid resistance, were inoculated with one 
colony and cultured overnight at 37°C while shaking (225 rpm, Thermo Scientific Heraeus 
Series 6000 Incubators, Thermo Scientific, USA). Cells grown in overnight culture were 
pelleted and plasmids were isolated using the QIAprep Spin Miniprep Kit (QIAGEN, 
Germany) according to the manufacturer´s protocol and eluted in 50 μl ddH2O. If larger 
amounts (max 500 μg) of plasmid DNA were desired, 100-200 μl of the overnight cultures 
were used to inoculate 50-100 ml LB medium. On the next day, plasmids were isolated with 
the QIAGEN Plasmid Maxi Kit (QIAGEN, Germany) according to the instruction manual. In 
the case of the BAC clones (BACPAC Resources Center, Oakland, USA), a BAC clone 
colony was inoculated into LB medium including 12,5 μg/ml chloramphenicol antibiotic and 
cultured overnight at 37°C while shaking (225rpm, Thermo Scientific Heraeus Series 6000 
Incubators, Thermo Scientific, USA). The next day the BAC DNA was recovered using the 
PhasePrep BAC DNA kit (Sigma, USA). 
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2.1.5 PCR purification and gel extraction 
 
PCR products were purified by QIAquick PCR Purification kit (QIAGEN, Germany) and 
eluted in 30 μl ddH2O. Restricted DNA fragments were separated from linearized vectors by 
gel electrophoresis (see 2.1.3), cut from the gel, extracted using the QIAquick Gel Extraction 
Kit (QIAGEN, Germany), and eluted in 30 μl ddH2O.    
 
2.1.6 Ligation  
 
DNA inserts and linearized vectors were ligated by T4 DNA ligase (Biolabs, UK) and Rapid 
DNA Ligation Kit (Roche, Switzerland) according to the manufacturer’s protocol. Ligations 
were incubated overnight at 16 °C or at room temperature (depending on selected ligase) 
before transformation. 
 
2.1.7 Transformation of electro- and chemically competent bacteria  
 
Electrocompetent Top10 cells (50 μl) were thawed on ice and mixed with 1-2 μl plasmid DNA 
(50-100 ng) or diluted ligation reaction (50-1000 ng). The reaction was transferred into a pre-
chilled 0.1 cm electroporation cuvette (BioRad, USA) and pulsed in an electroporator 
(EquiBio, France). The cells were resuspended in 1 ml Super Optimal broth with Catabolite 
repression (SOC) medium (Invitrogen, USA), incubated at 37 °C for 1 h while shaking 225 
rpm (Thermo Scientific Heraeus Series 6000 Incubators, Thermo Scientific, USA) and plated 
onto selection agar plates. For transformation of chemically competent cells, 50 μl cell 
suspension was mixed with 1 μl plasmid DNA (50-100 ng) or diluted ligation reaction (50-
1000 ng). The reaction was chilled on ice for 30 min, heat-shocked for 45 sec at 42 °C in a 
water bath or Thermomixer (Eppendorf, Germany), and placed on ice for additional 2 min. 
Subsequently, 0.250 ml SOC medium was added. Cells were regenerated at 37 °C for 1 h 
while shaking 225 rpm (Thermo Scientific Heraeus Series 6000 Incubators, Thermo 
Scientific, USA) and plated onto selection agar plates. 
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2.1.8 Site-directed mutagenesis 
 
The QuickChange Multi Site-Directed Mutagenesis Kit (Stratagene, USA) allowed a rapid 
and reliable method for site-directed mutagenesis of plasmid DNA. A single oligonucleotide 
carrying the mutated basepair was designed to mutagenize each site, using a double-
stranded DNA template. The three steps method consisted in a first step of a thermal cycling 
procedure to achieve multiple rounds of mutant strand synthesis (supercoiled double-
stranded DNA template), by using two or more synthetic oligonucleotide primers depending 
on the sample containing the desired mutations and the kit-provided enzyme blend featuring 
PfuTurbo DNA polymerase (6-fold higher fidelity in DNA synthesis than Taq DNA 
polymerase). In the second step, the thermal cycling reaction products were treated with the 
restriction endonuclease DpnI (specific for methylated DNA to digest parental DNA 
template). Finally, the reaction mixture, enriched for multiply mutated single stranded DNA, 
was transformed into XL10-Gold ultracompetent cells, where the mutant closed circle single 
stranded-DNA was converted into duplex form in vivo. Plasmids isolated from the 
transformants were then sent to sequence to identify clones bearing each of the desired 
mutations. 
 
2.2 Conditional miR-33 knockout mice 
2.2.1 Construction of miR-33 conditional knockout mice vectors.  
 
The generation of the miR-33 targeting vector was constructed based on pEZ-Frt-lox-DT 
vectors for conditional gene targeting, which contains a neomycin resistance gene driven by 
the promoter of the yeast gene encoding the glycolytic enzyme phospho-glycerate kinase 
(pGK promoter), flanked by FLP recognition target (FRT) sites, and a diphtheria toxin gene 
cassette. The strategy was designed to clone the loxP sites flanking the pre-miR-33 
sequence and the neomycin resistance cassette flanked by FRT sites. For the targeting 
vector a 4 kb fragment (5’ arm) extending upstream of the miR-33 coding region was 
digested with ClaI (Fermentas, Canada) and NotI (Fermentas, Canada) and ligated into the 
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pEZ-Frt-lox-DT. A 3.5 kb fragment (3’ arm) immediately downstream from the miR-33 was 
digested with XhoI (Fermentas, Canada) and ligated downstream of the loxP sites. The 
genomic fragment encompassing the mir-33 coding region (75bp) was digested with SacI 
(Fermentas, Canada) and ligated into the vector between the neomycin resistance, the loxP 
and the Frt-flanked cassettes. The targeting vectors were linearized with ScaI and 
electroporated into JM8.N4 C57BL/6 -derived embryonic stem (ES) cells (KONP, USA).  
 
2.2.2 Generation of miR-33 conditional KO mice 
 
Four hundred ES cell clones were isolated and analyzed for homologous recombination. 
Targeted ES clones carrying the properly miR-33 flanked allele were identified by PCR 
screening analysis (PCR primer sequences are listed in Table 2) with several primer sets 
using a special polymerase (Elongase Enzyme Mix, Invitrogen, USA) and one was used for 
injection into 3.5 days C57BL/6 blastocyst. High-percentage chimeric male mice were 
crossed to C57BL/6 females to achieve germline transmission of the targeted alleles.  The 
resulting chimeric mice were bred to C57BL/6 females to obtain germline transmission of the 
mutant allele. Heterozygous miR-33-neo/+ mice were intercrossed with deletor mice 
transgenic for Cre recombinase to remove the neomycin resistance cassette in vivo [111]. 
 
2.3 Mammalian cell culture  
2.3.1 Cell lines 
 
Cell lines HeLa, A549, Huh7, HEK293, MCF-7 and COS-7 were obtained from American 
Type Tissue Collection (USA) and cultured  in Dulbecco’s Modified Eagle Medium (DMEM, 
GIBCO, USA) containing 10% fetal bovine serum (FBS, GIBCO, USA) including 1% 
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, Biochrom, Germany) and 2mM L-
glutamine (GIBCO, USA) in a humidified with 5% CO2 at 37ºC in an incubator (Thermo 
Scientific Heraeus Series 6000 Incubators, Thermo Scientific, USA). Lipoprotein depleted 
serum (LPDS, GIBCO, USA) media contained 200ml DMEM and 20ml filtered LPDS, 2ml L-
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glutamine and 2ml penicillin/streptomycin (P/S). To synchronize the culture, cells were 
treated with Nocodazole (250 ng/ml, Sigma, USA) 24h post-transfection or with 2mM 
Thymidine (GIBCO, USA) for 18h. Stable miR-33 overexpressing cell lines were generated 
upon transduction with lentiviral vectors and selection with puromycin antibiotic (2 μg/ml) 
(GIBCO, USA). Briefly, murine miR-33 was amplified from genomic DNA and cloned into 
pSicoR, as described in Marquart et al. [99]; the green flourescent protein (GFP) cassette in 
pSicoR was then swapped with puromycin resistance cassette. Lentiviruses were obtained 
by cotransfection in HEK293 cells of empty or miR-33 pSicoR-Puro. Supernantants were 
collected 48h after transfection and used to transduce a variety of cell lines. 
 
2.3.2 Transfections  
 
Mammalian cell lines were either transfected with Lipofectamine 2000 Reagent (Invitrogen, 
USA) or Lipofectamine RNAiMAX (Invitrogen, USA). For transfection with Lipofectamine 
2000 Reagent, the cells were seeded 12 h prior transfection at a confluency of around 70-
75%. For transfections in 12-well plates, 2 μl Lipofectamine 200 Reagent was diluted in 582 
μl serum free medium (OptiMEM, Gibco, USA) and incubated for 5 min at room temperature. 
Plasmid DNA (1 μg/μl) was then added, vortexed, and incubated for at least 15 min at room 
temperature. Finally the transfection complex was added to the cell culture vessel in a drop 
wise manner while swirling. The expression of transfected constructs was assayed 24, 48 or 
72 h later. A549, HeLa and Huh7 cells were transfected with 40 nM miRIDIAN miRNA 
mimics (miR-33) or with 60 nM miRIDIAN miRNA inhibitors (inh-miR-33) (Dharmacon, USA) 
utilizing Oligofectamine (Invitrogen, USA). Oligofectamine is indicated for the transfection of 
oligonucleotides and short interfering RNA (siRNA) into eukaryotic cells. All experimental 
control samples were treated with an equal concentration of a non-targeting control mimic 
sequence (CM) or an inhibitor negative control sequence (CI) to control for non-sequence-
specific effects in all miRNA experiments. 
 
MATERIAL AND METHODS   25 
2.3.3 3’UTR luciferase reporter assay  
 
cDNA fragments corresponding to the entire 3’UTR of Ccnd1 and the three predicted 
miRNA target sites of Cdk6 were amplified by reverse transcription polymerase chain 
reaction (RT-PCR) from total RNA extracted from A549 cells with XhoI (Fermentas, 
Canada) and NotI (Fermentas, Canada) linkers. The PCR products were directionally 
cloned downstream of the Renilla luciferase open reading frame (ORF) of the 
psiCHECK2TM vector (Promega, USA) that also contained a constitutively expressed firefly 
luciferase gene, which was used to normalize transfections. Point mutations in the “ seed 
region” of predicted miR-33 sites within the 3’UTR of Ccnd1 and Cdk6 were generated 
using Multisite-QuickChange (Stratagene, USA) according to the manufacturer’s protocol. 
All constructs were confirmed by sequencing. COS-7 cells were plated into 12-well plates 
(Costar, USA) and co-transfected with 1μg of the indicated 3’UTR luciferase reporter 
vector and the miR-33 mimic or negative control miRNA mimic (CM) (Dharmacon, USA) 
using Lipofectamine 200 Reagent (Invitrogen, USA). Luciferase activity was measured 
using the Dual-Glow Luciferase Assay System (Promega, USA). Renilla luciferase activity 
was normalized to the corresponding firefly luciferase activity and plotted as a percentage 
of the control (cells co-transfected with the corresponding concentration of the control mimic 
sequence, CM).  
 
2.3.4 Cell cycle analysis 
 
Cells, cultured in DMEM supplemented with antibiotics (100 units of penicillin/ml and 100 
μg/ml of streptomycin) at 37°C in a humified atmosphere containing 5% CO2, were 
synchronized with 250 ng/ml Nocodazole (Sigma, USA) 24 h post transfection. 2 h before 
harvesting the culture, 5´Bromo-2´Deoxy-Uridine (BrdU) (B-5002, Sigma, USA) was added to 
the culture. At the end of the incubation the cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and fixed in 70% ethanol. After two additional washes with PBS, the 
pellet was resuspended first with 2N HCL to denaturize the DNA, then with 0.1 M 
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Na2B4O7·10 H2O pH 8.4 and finally blocked for 15 min at room temperature with PBS-0.5% 
Tween 20 (Sigma, USA) 1% Normal Goat Serum (NGS, Vector, USA). After blocking, the 
pellet was incubated with PBS-0.5% Tween 20 1% NGS and α-BrdU-FITC antibody (Anti-
BrdU-FITC Becton-Dickinson, USA) for 2 h at room temperature at dark. Finally, the cells 
were treated with 100 μg/ml Ribonuclease A (Roche, Switzerland) and labeled with 50 μg/ml 
propidium iodide (PI) for 1 h at 37°C. The cells were analyzed by flow cytometry 
(FACScalibur, Becton-Dickinson, USA) using selective gating to exclude the doublets of 
cells, and subjected to MODFIT analysis (Verity Software House, USA). 
 
2.3.5 Plasmid constructs and production of adenovirus 
 
A fragment containing miR-33 flanked by 150 bp upstream and 150 bp downstream of the 
genomic sequence was amplified by PCR using Platinum Pfx enzyme (Invitrogen, USA) from 
mouse genomic DNA obtained from tail biopsy specimens from C57BL/6 mice. The reverse 
primer used in the PCR contained the appropriate terminator sequence for RNA-pol-III 
(TTTTTCT). This fragment was cloned into the HpaI-XhoI sites of pSicoR-GFP (Addgene, 
USA), which provided a U6 promoter to control the expression of the transgene (and a GFP 
cassette under control of a cytomegalovirus promoter), thus generating pSicoR-miR33. The 
integrity of the clones was analyzed by sequencing. Adenoviruses were produced using the 
AdEasy Adenoviral System (Stratagene, USA) by cloning a XbaI-XhoI fragment containing 
the U6 promoter with or without the miR-33 sequences from the pSicoR vectors into 
pAdTrack (which also contains a GFP cassette). The pAdTrack and pAdTrack-miR33 vectors 
were electroporated into pAdeasy-1 cells to generate the final adenoviral vectors. 
Recombinant vectors were identified by the presence of a 4.5-kb PacI restriction fragment. 
These final vectors were transfected individually into AD293 cells (Stratagene, USA) for the 
production and amplification of the adenoviral particles. The adenoviruses were purified by 
caesium chloride (CsCl) gradient ultracentrifugation, and the titers were calculated to be 1 × 
1012 plaque-forming units (pfu/μL) for Ad-GFP and 1 × 1011 pfu/μL for Ad-miR33.  
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2.3.6 Cell proliferation assay 
 
Huh7, A549 and HeLa cells were grown in DMEM supplemented with 10% LPDS and 
transfected with control mimic (CM), miR-33, control miR inhibitor (CI) and antisense inhibitor 
of miR-33 (inh-miR-33). At the indicated times (24h, 48h and 72h), the viable cells were 
counted by trypan blue dye exclusion hemocytometer. 
 
2.3.7 Crystal violet staining 
 
After treatment, the medium was removed and the 24-well dishes were washed with PBS, 
fixed with 1% glutaraldehyde for 15 min, washed twice with PBS and stained with 100 μl of 
0.1% aqueous crystal violet solution for 20 min. Dishes were rinsed four times in tap water 
and allowed to air dry. If cell mass estimation was desired 100 μl of 10% acetic acid was 
added, and the content of each well was mixed before reading the absorbance at 595 nm.    
 
2.3.8 MTT assay 
 
MCF-7 cell viability was assessed by adding 20 μl of filter sterilised 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml in PBS) (R&D, USA) to each plate. 
Following a 5 h incubation period with MTT, medium was removed with a needle and syringe 
and the blue formazan crystals, trapped in the cells, was dissolved in 100 μl sterile dimethyl 
sulfoxide (DMSO) by incubating at 37 ºC for 30 min. The absorbance at 550 nm was 
measured with a plate reader (Model 680 Microplate Reader, BioRad, Germany). The growth 
curve was obtained from the absorbance related to the time course (DMSO as blank). 
 
2.4 Protein extraction and Immunoblotting 
 
Information regarding the applied antibodies is provided in the materials section 2.8.1.  
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2.4.1 Protein extraction from cell lysates  
 
Cells were lysed in ice-cold lysis buffer (50 mM Tris-HCl pH 7.5, 125 mM NaCl, 1% NP-40, 
5.3 mM NaF, 1.5 mM Na4P2O7 and 1mM orthovanadate, 175 mg/ml octylglucopyranoside), 
1 mg/ml of protease inhibitor cocktail (Roche, Switzerland) and 0.25 mg/ml 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF, Roche, Switzerland). After 5 min incubation 
on ice, cells lysates were sonicated (Sonicator3000, Qsonica LL, USA) for 20 sec (4x for 5 
sec) on ice and left rotating at 4°C for 1 h before the insoluble material was removed by 
centrifugation at 12000xg for 10 min. Protein supernatant was stored at -20°C till further use. 
 
2.4.2 Protein extraction from tissue lysates 
 
Briefly, liver tissue of wildtype as well as miR33-ASO and Control-ASO mice was 
homogenized in liquid nitrogen. Pulverized tissue (50 mg) was placed in a cooled dounce 
homogenizer (7 ml tight grinder, Wheaton, USA) and 1 ml ice cold lysis buffer (50 mM Tris-
HCl pH 7.5, 125 mM NaCl, 1% NP-40, 5.3 mM NaF, 1.5 mM Na4P2O7 and 1mM 
orthovanadate, 175 mg/ml octylglucopyranoside), 1 mg/ml of protease inhibitor cocktail 
(Roche, Switzerland) and 0.25 mg/ml AEBSF (Roche, Switzerland)) were added. The lysate 
was grinded 15x to disrupt the cells and protein solution was obtained after centrifugation 
(see 2.4.1) and stored at -20°C. 
 
2.4.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
 
For SDS-PAGE, the protein samples were mixed with 4x SDS loading buffer (300 mM Tris 
pH 6.8, 12% SDS, 0.6% bromphenol blue, 60% glycerol, 12% fresh β-mercaptoethanol) and 
denatured by cooking or not. 50 μg protein were loaded onto a polyacryl-amide gel 
composed of a 4% stacking gel and a 7,5-12% separating gel, and separated by gel 
electrophoresis (BioRad, Germany) in Running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS, pH 8.3) at 80 V until the sample focused in the stacking gel and then at 120 V until the 
dye ran off the gel.  
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2.4.4 Immunoblotting 
 
The separated proteins were transferred onto a nitrocellulose membrane in transfer buffer 
(25 mM Tris, 192 mM glycine, 10% methanol) using a wet blotter (BioRad, Germany). The 
transfer was conducted at 90 V for 3 h at 4°C. The membrane was blocked in Tris-Buffered 
Saline (TBST) and Tween 20 solution (125 mM Tris-HCl, 625 mM NaCl, 0.05% Tween 20, 
pH 8.0) containing 5% bovine serum albumin (BSA) for 30 min and incubated with the 
primary antibody dissolved in blocking buffer (aforementioned TBST containing 5% BSA) for 
1 h at room temperature or at 4 °C over night while shaking. The membrane was washed 3x 
in TBST for 10 min each and incubated with the secondary antibody diluted in TBST for 1 h 
at room temperature. After incubation, the membranes were washed 3x in TBST for 10 min. 
The immune complexes were detected with the LICOR Biotechnology detection system 
according to the manufacturer’s protocol (Oddyssey Infrared Imaging System, USA). Heat 
shock protein 90 (HSP90) was used to ensure equal loading. Densitometry analysis of the 
gels was carried out using the ImageJ software (NIH, USA, htt://rsbweb.nih.gov/ij/). 
 
2.5 Histology  
 
Information concerning the used antibodies is provided in the materials section 2.8.1.  
2.5.1 Frozen sections  
 
Liver samples of wildtype as well as 2’-O-methoxyethyl (2’MOE) phosphorothioate ASO 
(miR33-ASO) and control anti-sense oligonucleotides (Control-ASO) mice were fixed in 4% 
paraformaldehyde (PFA) at 4°C overnight and submerged in 30% sucrose at 4 °C during 5 h. 
Tissues were then embedded in cryomolds in Tissue Tek OCT compound (Sakura, Japan), 
snap frozen on dry ice, and stored at -80ºC. Frozen blocks were cut in eight μm thick 
sections (CM 1900, Leica, Germany), mounted on slides (Menzel, Germany), dried at room 
temperature for 30 min, and stored in airtight containers at -80ºC. The slides were warmed 
up to room temperature in closed containers for further immunohistochemical analysis.  
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2.5.2 Oil-Red-O staining 
 
Eight μm frozen sections were rehydrated and lipid droplets deposition was detected by Oil-
Red-O staining (Sigma, USA). Sections were rinsed with 60% isopropanol and stained for 20 
min with filtered freshly prepared Oil-Red-O solution (0.5% in isopropanol followed by a 60% 
dilution in distilled water). After two rinses with 60% isopropanol and distilled water, slides were 
counterstained with hematoxylin for 4 min, rinsed with water and mounted. Randomly digital 
images per section were taken with a Leica DM 4000B microscope (Leica, Germany).   
 
2.5.3 Immunohistofluorescence: Ki67 staining 
 
Frozen sections of eight μm thickness were rehydrated, blocked with 5% normal goat serum 
(NGS), and incubated with mouse anti-Ki67 (1:100, Abcam, USA) and counterstained with 
DAPI (0.2 ng/μl) (eBioscience, USA). Controls without primary antibodies were used as 
negative controls. Binding sites of the primary antibodies were revealed with Alexa-597 goat-
anti-mouse IgG (1:1000, Invitrogen, USA). Samples were analyzed with a fluorescence 
microscope at 597 nm (Nikon Eclipse E600, Kawasaki, and Kanagawa, Japan). 
 
2.6 Animals 
2.6.1 Mice  
 
C57BL/6J mice (Jackson Laboratories, USA) were kept in a pathogen-free animal facility with 
controlled humidity (50 ± 5 %), 12/12 hours light and dark cycle at 21ºC. Mice were fed ad 
libitum a standard diet. Twenty six weeks old male C57BL/6 mice were randomized into 3 
groups (n= 20 mice): no treatment (PBS, n=4), Control-ASO (n=8) or miR-33-ASO (n=8). The 
mice received a weekly subcutaneous injection of PBS, 10mg/Kg Control-ASO or miR-33-
ASO for 4 weeks. Animal experiments followed the German Ethical Committee for the Use 
and Care of Laboratory Animals, in accordance to the recommendations of the Society for 
Laboratory Animal Science (GV-SOLAS) and the Federation of European Laboratory Animal 
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Science Associations (FELASA). Likewise, all animal experiments were approved by the 
Institutional Animal Care Use Committee of New York University Medical Center. 
 
2.6.2 Surgical procedure 
 
All operations were performed under Isoflurane (DeltaSelect, Germany) anesthesia. A 70% 
partial hepatectomy (2/3 PH) was performed according to the technique described by Higgins 
and Anderson (Higgins  1931), revised by Mitchell and Willenbring in 2008 [112]. The mice 
were place into a plexiglas chamber for induction of anesthesia with 2% isoflurane and 2 
liters/min oxygen flow for a wild-type mouse of 25 g body weight. The abdomen was opened 
via midline incision and two thirds of the liver (median and left lobes) were removed. After the 
2/3 PH, the weights of regenerating liver were measured and the hepatic tissue was 
preserved for future processing at the following time points: 3, 8, 24 and 48 hours in the case 
of untreated mice and 5 days in the case of treated mice. The percentage of liver 
regeneration was calculated as a ratio between the weight of non removed lobes and the 
weight of total liver, and further normalized to the total body weight of the animal. 
 
2.7 Quantitative Real-Time PCR (qRT-PCR) 
2.7.1 Total RNA and miRNA isolation 
 
Mouse tissues were withdrawn immediately after sacrification and washed in ice-cold Hank’s 
balanced salt solution, flash-frozen in liquid nitrogen, pulverized and stored at -80ºC. Total 
RNA of individual tissues was isolated in parallel from no treatment, Control-ASO and miR-
33-ASO using RNeasy Kit (QIAGEN, Germany) according to the manufacturer’s protocol. 
Standard RNA isolation from cell lines was performed using RNeasy Kit (QIAGEN, Germany) 
and miRNeasy Kit (QIAGEN, Germany). The concentration and integrity of total RNA was 
measured using a NanoDrop 2000 (Thermo Scientific, USA). 
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2.7.2 cDNA-synthesis 
 
1000 ng total RNA was reverse transcribed using the Taqman RT Kit (Applied Biosystems, 
USA) in 20 μl reactions; following the manufacture’s protocol. Reactions were carried out at 
25°C for 10 min, 48ºC for 30 min, and 95ºC for 5 min. For miRNA quantification, 1000 ng 
total RNA was reverse transcribed using the RT2 miRNA First Strand kit (SABiosciences, 
USA) in 10 μl reactions, following the manufacture’s protocol. Reactions were carried out for 
2 hours at 37°C, 5 min at 95°C to degrade the RNA and to inactivate the reverse 
transcriptase, and 40 μl of ddH20 were added to each reaction prior storage at -20°C.  
 
2.7.3 qRT-PCR 
 
qRT-PCR reactions were performed in triplicates using the iQ SYBR green Supermix 
(BioRad, Germany) in a iCycler Real-Time Detection System (BioRad, Germany). The mRNA 
levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a 
housekeeping gene Gene-specific primers were designed using the Primer 3 software 
(Rozen, 200). The primer sequences used are listed in Table 2. Primers specific for human 
miR-33a, miR-33b, miR-16 (SABiosciences, USA) were used and values were normalized to 
human SNORD38b as housekeeping gene.  
No template and no reverse transcriptase were included and product quality was analyzed by 
gel electrophoresis and inspection of dissociation curves. PCR efficacy was determined for 
single reactions using DART-PCR Version 1.0 (Peirson, 2003) and mean PCR efficacy of 
gene-specific reactions was used for data analysis. Normalization and error propagation 
were calculated as described at the geNORM website (Vandesompele, 2002). The relative 
quantity of a specific transcript was calculated as:  
 
Q=E (Min(mean Ct of all samples)-Ct)   E: mean PCR efficiency 
Ct: threshold cycles 
MATERIAL AND METHODS   33 
Normalized expression levels of target genes were calculated by dividing the corresponding 
relative quantity by the normalization factor. Statistical significance was assessed using two-
tailed t test assuming unequal variance of the biological replicated.    
 
2.8 Materials 
2.8.1 Chemicals 
 
Chemicals were obtained from Sigma (USA) unless otherwise noted.  
 
2.8.2 Antibodies 
 
Table 1. Primary and secondary antibodies 
Antibody       Company        Dilution 
Primary antibodies 
Mouse monoclonal anti-CDK6    Cell Signaling  1:1000 
Mouse monoclonal anti-PCNA    Cell Signaling  1:1000 
Rabbit monoclonal anti-CCND1    Cell Signaling  1:1000 
Rabbit monoclonal anti-cleaved caspase-3 (Asp175) Cell Signaling  1:500  
Mouse monoclonal anti-HSP90    BD Bioscience 1:1000 
Mouse monoclonal anti-ABCA1    Abcam   1:1000 
Mouse monoclonal anti-Rb      Cell Signaling  1:1000  
Rabbit monoclonal anti-Phospho-Rb (Ser795)  Cell Signaling  1:500 
Mouse monoclonal anti-Ki67     Abcam   1:100 
Secondary antibodies for immunofluorescence 
 
Alexa-597 goat-anti-mouse IgG1    Invitrogen  1:1000 
 
Secondary antibodies for Immunoblotting 
 
Secondary fluorescently-labeled anti-mouse   Invitrogen  1:5000 
Secondary fluorescently-labeled anti-rabbit   Invitrogen  1:5000 
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2.8.3 Vectors and Constructs 
 
The generation of conditional transgenic and luciferase constructs is described in section 
2.1.8 and 2.3.3, respectively 
 
Table 2. Vectors and Constructs 
Plasmids    marker   description 
Empty vectors 
BAC Chori: RP24   Chloramphenicol  miR-33conditional mice 
pEZ-Frt-lox-DT   Neomycin   miR-33conditional mice  
psiCHECK™-2   Ampicillin   Luciferase Assay 
pCR™ 2.1-TOPO®   Ampicillin   Cloning Routine  
pCR™ II- TOPO®   Ampicillin   Cloning Routine 
pCR®-XL-TOPO®   Kanamycin   Difficult cloning routine  
pCMV-Sport 6    Ampicillin    Eukaryotic expression 
pSicoR-GFP    Ampicillin   Lentiviral packaging  
    
 
Constructs 
psiCHECK™-2- 3´UTR CDK6 BS1 + point mutation  
psiCHECK™-2- 3´UTR CDK6 BS2 + point mutation 
psiCHECK™-2- 3´UTR CDK6 BS3 + point mutation 
psiCHECK™-2- 3´UTR CDK6 CCND1 + point mutation 
pEZ-Frt-loxP-DT - miR-33 – SA – LA  
pSicoR-GFP-miR-33 
 
2.8.4 Synthetic oligonucleotide primers 
 
All primers were obtained from IDT (Integrated DNA Technologies) in 25 nmole DNA scale 
and resuspended in H20 to 100 pmol/μl (100mM) stock concentration.  
 
Table 3. Primer sequences 
 
   Gene     Sequence 
 
ABCA1 Fwd  5’-GGTTTGGAGATGGTTATACAATAGTTGT-3’  
ABCA1 Rev   5’-CCCGGAAACGCAAGTCC-3’ 
ABCG1 Fwd   5’-TCACCCAGTTCTGCATCCTCTT-3’ 
ABCG1 Rev   5’-GCAGATGTGTCAGGACCGAGT-3’ 
GAPDH Fwd  5’-AACTTTGGCATTGTGGAAGG-3’  
GAPDH Rev  5’-ACACATTGGGGGTAGGAACA-3’ 
SREBP2 Fwd  5’-GCGTTCTGGAGACCATGGA-3’  
SREBP2 Rev  5’-ACAAAGTTGCTCTGAAAACAAATCA-3’ 
SREBP1c Fwd 5’-ACTTCCCTGGCCTATTTGACC-3’  
SREBP1c Rev 5’-GGCATGGACGGGTACATCTT-3’ 
HMGCR Fwd  5’-CTTGTGGAATGCCTTGTGATTG -3’  
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HMGCR Rev  5’-AGCCGAAGCAGCACATGAT-3’ 
CDK6 Fwd   5’-ACC TTC GAG CAC CCC AAC GT-3’  
CDK6 Rev  5’-ACC ACA GCG TGA CGA CCA CT-3’ 
CDK8 Fwd   5’-GCC AGT TCA GTTACCTCGGGGA-3’  
CDK8 Rev  5’-GGGCAA AGCCCATGTCAGCAAT-3’ 
CDK19 Fwd   5’-TTT GCC GGC TGCCAG ATT CC-3’  
CDK19 Rev  5’-AGG CGA GAACTG GAG TGC TGA-3’ 
CyclinD1 Fwd  5’-TCG TTG CCC TCT GTG CCA CA-3’  
CyclinD1 Rev  5’-AGG CAG TCC GGG TCACACTT-3’ 
CyclinM1 Fwd  5’-CAC CCG CTT CTA CAA CCG GC-3’  
CyclinM1 Rev  5’-AGG GCT CCACTTCTGTGGCC-3’ 
ABCA1Not1  5’-AGCGGCCGCTTTCTGTAGACCAACAGAACTGTCA-3’ 
ABCA1Xho1  5’-AACTCGAGAGAATCCTGTTCATACGGGG-3’ 
CDK6PM1 F        5'-CGCCTAGTTTACTGTTTTGAAATCTTTGCAAGAGTGATTGCAGCTTTAT-3' 
CDK6PM1 R               5'-ATAAAGCTGCAATCACTCTTGCAAAGATTTCAAAACAGTAAACTAGGCG-3’ 
CDK6PM2 F         5'-TCATTTCTTATTTACTCCCTTTCTATATCTTTGCAATTCACAACCCAATTT-3' 
CDK6PM2 R               5'-GATGTATTAAAATTGGGTTGTGAATTGCAAAGATATAGAAAGGGAGTAA-3 
CDK6PM3 F        5'-ACCCTTACTTGAAAGTTTCTAATCTTAAGTTTTATGATTTGCAATAATATGTA-3' 
CDK6PM3 R              5'-CTAGCTGATACATATTATTGCAAATCATAAAACTTAAGATTAGAAACTTTCAA-3' 
CCND1PM F         5'-GGATGTTCATAAGGCCAGTATGATTTATATTTGCAATCTCCCCTTG-3' 
CCND1PM R              5'-CAAGGGGAGATTGCAAATATAAATCATACTGGCCTTATGAACATCC-3' 
miR-33 Fwd      5'-TCGACCTGTGGTGCATTGTAGTTGCATTGCATGTTCTGGCAATACCTGTGCA-3’  
miR-33 Rev   5'-CAGGTATTGCCAGAACATGCAATGCAACT ACAATGCACCACAGG-3’ 
miR-33 LA Fwd 5'-AAAGCGGCCGCAGGCCTGCCCTGACTGCC-3’ 
miR-33 LA Rev  5'-AAAATCGATGTGGGTGGAGGCCCAGGT-3’     
miR-33 SA Fwd 5'-AAACTCGAGGGCCGAGCCTGGGGTCTT-3’      
miR-33 SA Rev 5'-AAACTCGAGCTGCCCGCCAGGAGGTGT-3’ 
neo Fwd  5'-AGACAATCGGCTGCTCTGAT-3’ 
neo Rev  5'-ATACTTTCTCGGCAGGAGCA-3’ 
 
 
2.9 Statistics 
 
Experiments were performed in triplicates and repeated at least three times (3 biological and 
3 independent technical replicates). Data are presented as mean ± standard error of the 
mean (SEM) and number of replicates (n) is stated in the figure legends. Statistical 
significances were evaluated with the Student´s t-test (Excel-Office, Microsoft, USA) and 
differences were considered significant at the level of p<0.05. 
 
2.10 Computer analysis 
 
For the analysis of the nucleotide sequences, BLAST, BLAST2, MEGABLAST and NCBI 
(www.ncbi.nlm.nih.gov) were used. Mouse genome sequences, transcripts and putative 
proteins were downloaded from Ensembl (www.ensembl.org).  
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3  RESULTS 
3.1 miR-33 has predicted target genes involved in cell cycle and proliferation  
 
Since SREBPs regulate cellular proliferation and cell cycle progression and miR-33 is 
cotranscribed with SREBPs, in the current study, we decided to test the role of miR-33 in 
regulating these cellular functions. When looking at the Diana mirPath Software, designed to 
cover the need of a quick and easy interpretation of the involvement of a series of genes in 
biological processes, miR-33 was found to target genes involved in proliferation and cell 
cycle progression. As previously described by Fernández-Hernando’s laboratory and others, 
miR-33 was as well found to regulate cholesterol and fatty acid homeostasis by targeting 
other genes involved in these pathways (Table 4).  
 
Table 4.  miR-33 predicted pathways. KEGG Pathways enrichment in hsa-miR-33 target genes. Prediction 
software: TS5- using a score threshold (Predicted Target Genes: 240, Found in pathways: 50).  
 
KEGG 
Pathway 
Gene Name Found Genes  
- ln (p-value) 
ABC-transporters - 
General 
ABCA1 1  13.32 
Glioma 
PDGFRA, CDK6, 
CAMK2G, PIK3R3, 
CCND1 
5 
 
10.67 
Non-small cell lung 
cancer 
 
PDPK1, CDK6, PIK3R3, 
CCND1 
 
4 
 
7.57 
Fatty-acid metabolism ACADSB, HADHB, 
ALDH3A2 
 
3  7.27 
Prostate cancer PDGFRA, PDPK1, 
CREB5, PIK3R3, CCND1 
 
5 7.01 
 
Focal adhesion 
PDGFRA, VCL, PDPK1, 
RAC1, LAMC1, PIK3R3, 
CCND1 
 
 
7 
 
 
5.36 
Melanoma 
 
PDGFRA, CDK6, 
PIK3R3, CCND1 
 
4 
 
5.3 
Pancreatic cancer CDK6, RAC1, PIK3R3, 
CCND1 
4  5.19 
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To f u r t h e r  determine potential miR-33 targets involved in cell proliferation and cell 
cycle, a combination of bioinformatics tools for miRNA target prediction, such as 
TargetScan (http:/www.targetscan.org), miRanda (http:/www.microrna.org), DIANAmt 
(http://diana.cslab.ece.ntua.gr), miRDB (http://mirdb.org), miRWalk (http://www.ma.uni- 
heidelberg.de/aps/zmf/mirwalk) and PITA (http://genie.weizmann.ac.il) were used. This 
analysis confirmed that the 3’UTR of the cyclin dependent kinases (Cdk6, Cdk8 and Cdk19), 
Ccnd1 and Ccnd2, p53, Pten, Myc and mitogen-activated protein kinases (Map3k1, 
Map3k7, Mapk1, Mapk3, Mapk6, Mapk10 and Mapk14) have predicted binding sites for 
miR-33 (Table 5). 
Table 5.  miR-33 predicted target genes. Gene target prediction based on TargetScan, miRanda, DIANAmt, 
miRDB and PITA. The five algorithms were applied to databases of 3'UTR sequences. The potential predicted 
targets for miR-33 are marked according to the algorithm used. 
Gene DIANAmT miRanda  miRDB  miRWalk PITA TargetScan 
ABCA1 ✓ ✓ ✓ ✓ ✓ ✓ 
CDK6 ✓  ✓ ✓ ✓ ✓ 
CDK8 ✓ ✓  ✓ ✓ ✓ 
CDK19 ✓ ✓  ✓ ✓ ✓ 
CCND1  ✓  ✓ ✓ ✓ 
CCND2  ✓  ✓ ✓ ✓ 
MAP3K1 ✓ ✓ ✓ ✓ ✓ ✓ 
MAP3K7 ✓ ✓  ✓   
MAPK1 ✓ ✓  ✓   
MAPK3 ✓ ✓  ✓   
MAPK6 ✓ ✓  ✓ ✓ ✓ 
MAPK10 ✓ ✓  ✓ ✓  
MAPK14 ✓ ✓ ✓ ✓ ✓ ✓ 
p53 ✓ ✓  ✓ ✓ ✓ 
PIK3R3 ✓ ✓  ✓ ✓ ✓ 
PTEN  ✓  ✓ ✓ ✓ 
MYC  ✓  ✓ ✓ ✓ 
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3.2 miR-33 regulates posttranscriptionally CDK6 and CCND1 expression 
 
To determine the effect of miR-33 on the mRNA expression of CDK6, CDK8, CDK19, 
CCND1, CCNM1, three different cell lines were transfected with miR-33 or a control 
sequence. Transfection of Huh7 cells with miR-33 (40-fold increased expression, data not 
shown) significantly inhibited the mRNA levels of CDK6 and ABCA1, a previous identified 
target of miR-33 (Fig. 5A). However, mRNA levels of CDK8, CDK19, CCND1 and CCNM1 
were not significantly downregulated.  Similar results were observed in A549 and HeLa cells 
transfected with miR-33 or control (Fig. 5C and 5E, respectively). To enhance the activity of 
miR-33, HeLa cells were further cultivated in absence of cholesterol (LPDS medium) to avoid 
endogenous repression of the miR-33. As seen in Fig. 5F, CDK6 and ABCA1 mRNA levels 
were significantly decreased. Notably, endogenous inhibition of miR-33 using anti-miR-33 
oligonucleotides (2.5-fold decrease, data not shown) increased mRNA expression of CDK6 
A B
 
C D
 
E F 
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and ABCA1 in Huh7 and A549 cell lines (Fig. 5B and 5D).  
Figure 5. Post-transcriptional regulation of cell cycle genes and ABCA1 by miR-33. Quantitative RT-PCR 
expression profile of selected miR-33 predicted target genes: Cdk6, Cdk8, Cdk19, Ccnd1, Ccnm1 and Abca1 in 
(A) human liver Huh7 cell line overexpressing miR-33, (B) human liver Huh7 cell line overexpressing anti-miR-33, 
(C) human lung A549 cell line overexpressing miR-33, (D) human lung A549 cell line overexpressing anti-miR-33, 
(E) human cervical HeLa cell line overexpressing miR-33 and (F) human cervical HeLa cell line overexpressing 
miR-33 cultured in cholesterol free medium. Dotted lines at 1 indicate value corresponding to control-miR or 
control inhibitor (random sequence molecules that have been extensively tested in human and mouse cell lines 
and tissues and validated to produce no identifiable effects on known miRNA function). Data are the mean ± 
SEM and are representative of ≥ 3 experiments. * p ≤ 0.05. 
 
 
Since the expression level of CCND1 and CCNM1 varies along the cell cycle, Huh7 and 
A549 cells were synchronized in the G1 phase using a double thymidine block, which 
arrested the cells in the early S phase (Fig. 6A). As seen in Fig. 6B, transfection of Huh7 
(upper panel) and A549 (lower panel) with miR-33 significantly inhibited CDK6, CCND1 
and ABCA1 mRNA levels. 
 
 
 
 
 
Figure 6. Posttranscriptional regulation of cell cycle genes and ABCA1 by miR-33 in synchronized Huh7 
and A549 cells. (A) Flow cytometry analysis of Huh7 cells (upper panels) and A549 cells (bottom panels) 
synchronized using double thymidine block (right panels).  (B) Quantitative RT-PCR analysis of selected miR-33 
predicted targets in Huh7 and A549 cells transfected with control-miR (CM) or miR-33 after thymidine block 
synchronization. Dotted lines at 1 indicate value corresponding to CM. Data are the mean ± SEM and are 
representative of ≥ 3 experiments. * p ≤ 0.05. 
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3.3 miR-33 regulates CDK6 and CCND1 protein levels in Huh7 and A549 cells 
 
Huh7 cells were transfected with control-miR (CM) or miR-33 (Fig. 7, upper panel) and 
protein content was analyzed by Western Blot after 48 h upon transfection. Cells transfected 
with miR-33 showed significantly decreased protein levels of ABCA1, CDK6 and CCND1 
(Fig. 7, upper panel). Conversely, when cells were transfected with the inhibitor of miR-33 
(Inh-miR-33) (Fig.7, bottom panel) the content of the proteins increased significantly when 
compared to the control inhibitor (CI) (Fig.7, bottom panel). 
 
Figure 7. miR-33 overexpression inhibits CDK6 and CCND1 protein expression in Huh7 cells. Western Blot 
analysis of CDK6, CCND1 and ABCA1 expression from Huh7 cells transfected with CM or miR-33 (A) or control-
inhibitor (CI) and Inh-miR-33 (B). Heat shock protein (HSP)90 bands are the loading control. Dotted lines at 1 
indicate value corresponding to CM or CI. Data are the mean ± SEM and are representative of ≥ 3 experiments * 
p ≤ 0.05. 
 
In a time course experiment, A549 cells were transfected for 24, 48 and 72 h with either CM 
or miR-33 and protein content was similarly analyzed by Western Blot at the indicated time 
A
   
 
B
 
  
 
RESULTS   41 
points after transfection (Fig. 8). In Fig. 8A a downregulation of CDK6 and CCND1 is 
illustrated and confirms the results shown in Fig. 7. 
To further ascertain that downregulation of CDK6 and CCND1 have a functional role on the 
phosphorylation of their downtream signaling molecule, the reinoblastoma protein (RB), and 
thus on cell cycle progression, the total and phosphorylated RB levels were measured. As 
seen in Fig. 8 downregulation of CDK6/CCND1 provoked by miR-33 transfection also 
provoked a downregulation of phosphorylated RB.    
 
Figure 8. miR-33 regulates CCND1/CDK6 signaling in A549 cells. Western Blot analysis of RB, P-RB, CDK6 
and CCND1 expression from Á549 cells transfected with CM and miR-33 for 24, 48 and 72 h. After transfection 
miR-33 impairs CCND1/CDK6 signaling by reducing RB phosphorylation in A549 cells. Dotted lines at 1 indicate 
value corresponding to CM. Data are the mean ± SEM and are representative of ≥ 3 experiments. * p ≤ 0.05   
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Phosphorylation of RB by the CDK6/CCND1 complex allows the cell cycle progress through 
G1 into S phase. Decreased phosphorylation of RB by miR-33 transfection indicates a 
possible role of miR-33 in the cell cycle progression. Altogether, the mRNA and the protein 
data strongly suggest that miR-33 coordinates genes regulating cell cycle progression. 
 
3.4 miR-33 directly targets the 3’UTR of Cdk6 and Ccnd1 
 
The human Cdk6 and Ccnd1 3’UTR have three and one computationally predicted miR-33 
binding sites respectively (Fig. 9A and 9B). All the predicted binding sites are evolutionary 
conserved (Fig. 9C and 9D). 
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Figure 9. Putative 3´UTR target sites of CDK6 and CCND1 regulated by miR-33 and conservation among 
species.  Sequence alignment of the human hsa-miR-33 mature sequence with the binding sites of the human 
CDK6 3’UTR (A) and human CCND1 3’UTR (B). Relative position of the binding sites is indicated (-). CDK6 (C) 
and CCDN1 (D) miR-33 mature sequence binding site conservation between species. Hsa=human; 
Ptr=chimpanzee; Mmu=mouse; Rno=rat; Ocu=cat). 
  
 
 
To directly assess whether miR-33 d i r e c t l y  targets CDK6 and CCND1, reporter 
constructs with the luciferase coding sequence fused to the 3’UTR of these genes w e r e  
g e n e r a t e d . In the case of CDK6 3’UTR, due to the long fragment of the sequence 
(more than 10 kB), the sequence was splitted into three parts, each of them containing 
one of the predicted binding sites for miR-33. miR-33 markedly repressed the luciferase 
reporter  activity of the Cdk6 and Ccnd1 3’UTR constructs (Fig. 10A and 10B, respectively). 
Mutation of the miR-33 target sites relieved miR-33 repression of CDK6 and CCND1 3’UTR 
activity, clearly demonstrating the direct interaction of miR-33 with these predicted 
sequences (Fig. 10A and 10B, respectively).  
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Figure 10.  miR-33  specifically  targets  the  3’UTR  of  Cdk6  and  Ccnd1. Luciferase reporter activity in 
COS-7 cells transfected with CM or miR-33 of the Cdk6 (A) and  Ccnd1 (B) 3’UTR containing the indicated point 
mutations (PM) in the miR-33 target sites. Data are expressed as mean % of the 3’UTR activity of control miR ± 
SEM and are representative of ≥ 3 experiments. * p ≤ 0.05 
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3.5 miR-33 regulates cell proliferation and cell cycle progression 
 
To asses the role of miR-33 in regulating cell proliferation, Huh7, A549 and HeLa cells were 
transfected with miR-33 or CM and the viable cell number was measured at different time 
points. As seen in Fig. 11A and 11C, overexpression of miR-33 inhibited cell growth in Huh7 
and A549 cells compared to CM. Contrary, when treated with an antagonist of endogenous 
miR-33, increased cell proliferation in Huh7 and A549 cells was observed compared to CI 
(Fig. 11B and 11D). However, the inhibition of cell proliferation through miR-33 
overexpression took place independently from cholesterol content in the medium (Fig. 11E 
and 11F). 
Figure 11. miR-33 inhibits cell proliferation. Time course analysis of the effects of overexpression (A, C, E & 
F) or inhibition (B & D) of miR-33 on cell proliferation. Huh7, A549 and HeLa cells were cultured in 
cho les te ro l  (E )  or  cholesterol-free (A-D & F) medium and transfected with CM, miR-33, CI and Inh-miR-33. 
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At the indicated times, the viable cells were counted. Data correspond to means ± SEM and are representative of 
≥ 3 experiments. * p ≤ 0.05. 
 
To verify these observations, in collaboration with Angel Baldán´s group from St Louis 
University (UCLA, USA), cell growth was assessed by Crystal Violet Staining and MTTassay 
in HeLa and MCF7 cells transfected with miR-33 with a lentivirus transfection system.  
 
Figure 12. Proliferation ability decreases with miR-33. HeLa (A & C) and MCF-7 (B & D) cells stably 
transduced with empty or miR-33 overexpression lentiviral vectors were serum starved for 48 h in DMEM 
supplemented with 0.2% BSA. In two independent experiments, growing following the return serum was assayed 
at 24, 48 and 72 h qualitatively by Crystal Violet Staining (A & B) and quantitatively by MTT assay (Cayman 
Chemical Inc.) (C & D). Data are represented as mean ± SEM. ** p ≤ 0.01. 
 
As illustrated in Figure 12, HeLa (Fig. 12A and 12C) as well as MCF7 cells (Fig. 12B and 
12D) showed a reduced cell growth when transfected with miR-33 compared to empty 
control vector. Those results were ascertained by the Crystal Violet Staining as well as by 
MTT-assay.  
Further, stably transfected HeLa cells were used to study the impact of miR-33 
overexpression on the cellular response to mitogenic stimuli. Hence, the cells were 
serum-starved for 72 h and  se rum was  reintroduced, as described in Methods 2.3.8.  
As shown in Figure 13 (upper panel), the expression of CDK6 and CCND1 was induced 
A C
 
B D
 
RESULTS   47 
when cells were switched form BSA to serum, and the expression of both genes was 
reduced in cells overexpressing miR-33 as compared to controls. Of note,  
miR-33–dependent repression of these targets resulted in increased mRNA levels of CDK4, 
CCND2 and CCND3 (Fig. 13, bottom panel).  
The exact molecular events that lead to these compensatory changes remain obscure, 
though; these results demonstrate that miR-33 regulates cell proliferation via targeting CDK6 
and CCND1. Most of the mitogenic pathways result in the transcriptional induction of D-type 
cyclins and the subsequent activation of cyclin-dependent kinases (CDKs) such as 
CDK4 and CDK6. The active CDK4/6-cyclin D complexes then inactivate the RB, leading 
to the EF-dependent transcription of specific cell cycle genes and progression throughout 
the cell cycle. 
 
Figure 13. Compensatory effects of miR-33 inhibition. HeLa cells stably transduced with empty (LV-empty) or 
miR-33 overexpression (LV-miR-33) lentiviral vectors were serum starved for forty-eight hours in DMEM 
supplemented with 0.2% BSA. mRNA levels of CDK6, CDK4, CCND1, CCND2, and CCND3 were determined at 
the end of the 48 h starvation, as well as at 8 and 24 h following  the return of serum (DMEM supplemented with 
10%FBS). Data are represented as mean ± SEM. ** p ≤ 0.05. 
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3.6 miR-33 induces G1 arrest  
 
To assess the effect of miR-33 on cell cycle progression, Huh7 cells were transfected with 
CM or mIR-33 and further synchronized in mitosis by nocodazole treatment during 24 h. 
As seen in Figure 14 control cells were released from G1 phase, as showed by a 
progressing lower relative amount of diploid cells (2N). Contrary, cells transfected with miR-
33 were arrested in G1 phase after release from mitosis, suggesting an important role of 
miR-33 in regulating the G1/S transition.  
 
 
Figure 14. miR-33 induces G1-arrest. Cell cycle distribution of Huh7 cells transfected with CM or miR-33 and 
synchronized in G2/M with nocodazole. After 24 h of treatment with nocodazole, cells were washed and released 
of the G2/M cell cycle arrest. At the indicated times, cells were stained with propidium iodide and analyzed by flow 
cytometry. 2N: cells have diploid DNA content (G0/G1 phase); 4N (G2/M): cells have tetraploid DNA content. 
Data correspond to a representative experiment among three that gave similar results. FL2-A corresponds to the 
fluorescence emitted by propidium iodide bound to DNA, which is measured by cytometry in channel 2 (FL2). To 
avoid the eventual presence of doublets, among the parameters given by the cytometer area (FL2-A) is preferred 
in order to quantify the amount of DNA present in the cell. 
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The kinetics of miR-33 mRNA expression during cell cycle progression was analyzed as 
next after 4, 8, 12 and 24 h in nocodazole synchronized Huh7 cells. As shown in Fig. 15A 
and 15B, miR-33a, miR-33b, SREBP1 and SREBP2 levels decreased after releasing the 
cells from mitosis. The results emphasize once more the functional role of miR-33 in 
regulating the expression of CDK6, CCND1 and ABCA1. Indeed, miR-33 levels were 
inversely correlated with the expression of CDK6, CCND1 (Fig. 15D) and ABCA1 (Fig. 
15C), suggesting a functional role for miR-33 in regulating the expression of these genes. 
Moreover, miR-16 is a marker for G1 phase and inversely correlates with miR-33 expression 
(Fig. 15A). The inhibition of ABCA1 and the increased expression of genes involved in 
cellular cholesterol uptake (low-density lipoprotein receptor, LDLr) and cholesterol 
biosynthesis (3-hydroxy-3methylglutaryl coenzyme A reductase, HMGCR) (Fig. 15E) 
resulted in an increase in cellular cholesterol levels (Fig. 15F). 
 
 
 
 
  
 
 
 
 
 
 
RESULTS   50 
 
 
Figure 15. mir-33 expression levels correlate inversely with its predicted target genes during cell cycle 
progression. (A to E) Quantitative RT-PCR analysis of miR-33a/b, SREBP-2, SREBP-1, ABCA1, CDK6, 
CCND1, LDLR and HMGCR in human hepatic Huh7 cells synchronized with nocodazole for 24 h. (F) Total 
cholesterol content was measured at 0, 4, 8, 12 and 24h after nocodazole release. Data are the 
mean ± SEM and are representative of ≥ 3 experiments which gave similar results. 
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3.7 Antagonism of miR-33 in mice promotes liver regeneration 
The liver is pivotally positioned in the regulation of the body´s metabolic homeostasis 
of lipids, carbohydrates and vitamins. Consequently, the liver has evolved complex 
regenerative mechanisms to respond to chemical, traumatic or infectious injuries [113]. 
One of the most extensively characterized model systems to study liver regeneration is the 
partial hepatectomy (2/3 PH) in rodents. In this model, the left and medial lobes of the liver 
are excised, resulting in removal of 70% of the hepatic mass. Within minutes, hepatocytes 
then undergo a coordinated cellular activation termed the acute phase response. As a result 
of the acute response, the hepatocyte initiates the transcription of more than 100 early 
genes, accumulates triacylglycerol and cholesterol esters in intracellular lipid droplets, and 
progresses through the cell cycle. Lipid droplet formation is an essential part of the 
proliferative response during liver regeneration. By compensatory hyperplasia, the 
regenerative process reestablishes the original liver mass in approximately 1 week, after 
which hepatocytes return to a quiescent state. 
To analyze the role of miR-33 in a physiological model of cellular proliferation and regeneration  
2/3 PH was performed in mice and Ki67 expression (Fig. 17) as well as lipid accumulation 
(Fig. 18) were assessed as markers for proliferation and regeneration, respectively (following 
the time course shown in Fig. 16).  
 
 
Figure 16. Experimental outline of liver regeneration after 2/3 PH. Time-course analysis from liver of mice 
(n=3) subjected to 2/3 PH. Samples were analyzed at 0, 3, 8, 24 and 48 h after 2/3 PH. 
 
 
 2/3 PH 
t=0 h 
  n=3 
t=3 h t=8 h t=24 h t=48 h 
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As seen in Fig. 17, a significant number of Ki67 positive cells were observed in sections 
of livers at 48h following 2/3 PH. Cell cycle entry and progression of hepatocytes after 2/3 
PH occurred not only rapidly, but also in a synchronized dependent fashion. Most 
hepatocytes have entered S phase by 72 hours after 2/3 PH in adult C57BL/6 mice. 
Confirming our previous findings, 2/3 PH in such mice caused decreased mir-33 expression 
that was detectable at 8 hours, peaked between 8 and 24 hours, and returned to almost 
normal levels by 72 hours after the surgery (Fig. 19). The timing of the miR-33 decay 
suggests a role in the regulation of cell cycle events preceding the S phase. 
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Figure 17. Liver regeneration after 2/3 PH. Time course analysis of Ki67 positive cells from liver 
sections of mice subjected to 2/3 PH. The computed assisted quantification of the proliferating cells 
(red) vs. the total number of cells (blue) is shown at the graph. Data are mean ± SEM (n=6 mice). 
 
In agreement with the proliferation status and the Ki67 staining (Fig. 17), the 
accumulation of lipid-droplets was similar in the liver after 2/3 PH. After partial 
hepatectomy, the levels of fatty acids in the plasma increase several fold, leading to 
the intracellular accumulation of lipids and the formation of numerous cytosolic lipid 
droplets [114]. Eight hours after partial hepatectomy, the hepatocytes of mice 
accumulated enlarged lipid droplets in the cytosol (Fig. 18), confirming the data 
shown by Glende et al. 
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Figure 18. Intracellular lipid accumulation in the liver after 2/3 PH. Time course analysis of  
Oil-red-O positive cells from liver sections of mice subjected to 2/3 PH. The computed assisted 
quantification of the lipid droplets (red) vs. the total number of cells (blue) is shown in the graph. 
Data are mean ± SEM (n=6 mice). 
 
To determine whether or not miR-33 plays a role during liver regeneration, miR-33, SREBP2, 
CDK6 and CCDND1 levels were measured in the same 2/3 PH model.  
The expression of miR-33 (Fig. 19, upper panel) correlated inversely with both the 
proliferative status of the liver (Fig. 17) and the mRNA expression of CDK6 and CCND1 
(Fig. 19, middle panel), thus suggesting a role for miR-33 in regulating liver regeneration. 
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Similar results were obtained when the expression of proliferating cell-nuclear antigen 
(PCNA) in liver lysates was analyzed by Western blot (Fig.19, bottom panel).  
 
Figure 19. Liver regeneration after 2/3 PH causes a rapid induction of CCND1 expression and 
miR-33 downregulation. Time course mRNA expression analysis of miR-33, SREBP-2 (upper), 
CDK6 and CCND1 (middle) and Western blot analysis (bottom) of PCNA and cleaved caspase 3 
expression from liver lysates of mice subjected to 2/3 PH. Data are mean ± SEM (n=6 mice). 
 
To assess the effects of inhibiting miR-33 in the 2/3 PH model, C57BL/6 mice were treated 
with 10 mg/Kg of 2’fluoro/methoxyethyl-modified (2’F/MOE- modified) phosphorothioate 
backbone antisense miR-33 oligonucleotides (miR-33-ASO), control anti-miR (Control-
ASO) or PBS (untreated) once a week for one month. The experimental outline of miR-33-
therapy is illustrated in Figure 20. 
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Figure 20. Experimental outline of miR-33-ASO, Control-ASO or PBS treatment in mice. C57BL/6 mice (n 
= 8 per group) were treated for one month prior 2/3 PH. The analysis was done at day 0 (before 2/3 PH) and at 
day 5 (after 2/3 PH).  
 
This subcutaneous or intraperitoneal antisense therapy has been used successfully in mice 
to inhibit the function of various miRNAs and to increase expression of their target genes, 
with no apparent toxicity [105].  To determine the efficacy of the anti-miR-33 treatment, the 
hepatic expression of miR-33 and its target genes (Cdk6, Ccnd1 and Abca1) were 
measured after 4 weeks of treatment (see Figure 21A and 21C). Levels of miR-33, detected 
by qRT-PCR, were decreased by more than 50% in anti-miR-33-treated mice (miR-33-
ASO) compared with controls (Control-ASO) (data not shown). Consistent with these 
results, the expression of ABCA1, CDK6 and CCND1 was increased in the livers of the 
mice treated with anti-miR-33 before the 2/3 PH (t=0, Fig. 21B) and during liver 
regeneration (t=5 days after 2/3 PH, Fig. 21D). Of note, the expression of the proliferative 
marker PCNA was also increased in mice treated with anti-miR-33 (Fig. 21B and 21D).  
 
 
 
 
 
 
Control-ASO 
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  2/3 PH 
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Figure 21.  Anti-miR-33 treatment reduces miR-33 expression in the liver and causes 
derepression of its target genes. Mice were treated for 4 weeks with PBS (no treatment) or control 
anti-miR (Control-ASO) or anti-miR-33 2’F/MOE oligonucleotides (miR-33-ASO). Expression of miR-
33 target genes (ABCA1, CDK6, CCND1), and proliferation marker (PCNA) and miR-33 host gene 
(Srebp2) in the liver was quantified by RT-PCR (A) and by Western blot (B) at time 0 (A and B) and 5 
days after (C and D) 2/3 PH. The representative Western Blot analysis (B and D) shows that the 
inhibition of miR-33 in vivo for 4 weeks increased the expression of PCNA, CDK6, CCND1 and 
ABCA1. Relative density analysis is shown in the right part. Dotted line positioned at one represents 
the normalized values of control mice. The data are presented as the mean ± SEM and are 
representative of 3 experiments * p < 0.05.      
 
Further, the effects of anti-miR-33 oligonucleotides in liver regeneration after 2/3 PH were 
investigated (Fig. 22). Mice treated with miR-33-ASO have significantly more 
proliferating hepatocytes at day 5 after 2/3 PH as compared to controls (Fig. 22A). The 
regeneration index, given as the increase in the liver-to-body mass ratio, was calculated as 
described in Methods 2.6.2. As seen in Fig. 22B, mice treated with anti-miR-33 
oligonucleotides showed an accelerated liver regeneration suggesting that anti-miR-33 
therapy might be useful for treating liver disease.  
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Figure 22. Inhibition of miR-33 with miR-33-ASO in vivo increases liver regeneration. Mice treated with 
miR-33-ASO proliferated more that the mice treated with ASO Control after 2/3 PH (A) as shown by Ki67 
staining, a proliferation marker. (B) Effect of miR-33-ASO treatment on liver regeneration after partial 
hepatectomy. The body weight recovery was used to calculate the percentage of liver regeneration after 2/3 PH 
vs. control animals (dotted line indicates 100% liver regeneration). The data are presented as the mean ± SEM 
and are representative of 8 experiments * p < 0.05 
 
In the presented liver regeneration model, miR-33 inversely correlated with CDK6, CCD1 
and PCNA expression and anti-miR-33 therapy provoked an increased of those targets.  
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Taken together, these results suggest that miR-33 is involved in cell cycle progression 
and cellular proliferation via the regulation of multiple proteins. Figure 23 is a pontential 
working hypothesis for miR-33. 
 
Figure 23. A model for miR-33-mediated regulation of cell proliferation and cell cycle progression. miR-33 
induces a G1 arrest through negative effects on cell cycle related proteins including CDK6 and CCND1. Other 
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molecules (e.g. p53, PTEN, Bcl-2) involved in the cell cycle are targets or predicted targets for miR-33. (Modified 
from Cirera-Salinas et al.) 
 
3.8 Construction of a conditional miR-33 knockout  
 
To further explore the functions of mir-33, a conditional knockout mouse model was designed 
and generated. A targeting vector was created to “flox” the miR-33 genomic coding region in 
the intron 17 of the Srebf2 gene. This vector contained a neomycin selection cassette 
flanked by site-specific flippase recognition target (FRT) recombination sites in intron 17 (Fig. 
24). To clone the left and right homologous recombination regions, genomic intron 17 from 
Srebf2 gene sequences were obtained by PCR of genomic DNA from BAC clones library 
(CHORI Hospital, BACPAC Resources Center, USA). The miR-33 genomic coding region 
and the flanking regions were step-wise inserted into a vector backbone already containing 
the appropriate loxP recombination sites (pEZ-Frt-lox-DT). As next the neomycin selection 
cassette flanked by FRT sites and the genomic miR-33 coding region flanked by the loxP 
sites were first excised from pEZ-Frt-lox-DT and then inserted into the right homologous 
recombination region in the intron 17. 
After integration into the Srebf2 locus, this construct gave rise to a bicistronic mRNA that is 
transcribed from the endogenous expression of Srebf2 promoter. Thus the expression of the 
neomycin selection gene depended on the endogenous expression of Srebf2 in embrionic 
stem (ES) cells. The selection cassette could be removed in vivo from the conditional allele 
with a site-specific flippase recombinase by crossing animals harboring the modified 
conditional miR-33 allele with a FLP expression deleter strain, as described by Farley et al. 
[115]. After the correct removal of the neomycin selection cassette, genomic miR-33 coding 
region was flanked by only two loxP sites in the intron 17; termed flox allele (flox).          
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Figure 24. Strategy to generate a miR-33 conditional knockout mouse by homologous recombination. The 
loxP and the FRT sites flanking the neomycin cassette were inserted into the intron 17 of the Srebf2 gene flanking 
the miR-33 genomic coding region. Neomycin cassette was removed in the mouse germ line by crossing 
heterozygous mice to a recombinase-flippase transgenic mouse.   
 
 
3.9 Generation of conditional knockout mice 
 
Mouse-derived ES cells (JM8.A3) were transfected with the targeting vector, selected with 
neomycin and grown in culture. Positive ES cell clones were identified by PCR, using 
different primers combinations located upstream and downstream of the integration site. 
After selection, a properly targeted ES cell clone was injected in C57BL/6 blastocysts to 
generate chimeras. Several chimeric males were obtained and crossed with C57BL/6 
females. PCR-based  genotyping of their agouti progenies showed successfully transmission 
of the mutant allele to the germ line. To remove the neo selection cassette, animals carrying 
the miR-33neo/+ allele were bred with expressing deleter mice, as described by Rodriguez et 
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al. [116]. To detect the flox and the wild type (wt) allele, the progenies were genotyped by 
PCR. As expected, miR-33 was flanked by loxP sites and a single FRT remained in intron 
17. The miR-33flox/+ animals were further intercrossed and bred till homozygosity (flox/flox). 
These miR-33flox/flox mice were phenotypically normal and fertile, indicating that the loxP sites 
did not interfere with the normal processing of the miR-33 mRNA. Finally, it was very 
important to prove that miR-33 can be deleted by introducing a Cre recombinase in vivo. The 
Cre-mediated excision of miR-33 resulted in deletion of the miR-33.  
In summary, a conditional miR-33 mouse model was generated. The selection cassette was 
successfully removed in vivo. Homozygous animals for the floxed miR-33 allele (miR-
33flox/flox) develop normally, indicating that the loxP sites did not interfere with the function of 
miR-33 or its host gene Srebf2. Floxed miR-33 could be deleted in vivo by crossing with early 
Cre-deleter mice. The tool to further study the role of miR-33 in vivo was thus established in 
our laboratory.       
DISCUSSION   63 
4 DISCUSSION 
 
Since the discovery of the first miRNA, lin-4, in 1993 [60, 61], this family of previously 
unknown molecules has earned a superordinate position among the central mechanisms of 
gene activity regulation. Computational analyses predicted that the expression of 40-60% of 
all genes is regulated by miRNAs and they are involved in the control of all biological 
processes [117]. The present work aimed to characterize the relation between miR-33, 
cholesterol, fatty acid oxidation and carbohydrate metabolism, as well as to identify the 
regulatory properties of miR-33 in the cell cycle.  
 
4.1 miR-33 modulates cholesterol, fatty acid oxidation and carbohydrate homeostasis 
 
Our understanding of cholesterol homeostasis has significantly advanced over the past 
years. Much insight has been gained into the transport pathways that regulate sterol 
trafficking and distribution within cells and much progress has been made in understanding 
the regulatory mechanisms that control cholesterol uptake and efflux. In this context, recent 
studies indicated that miRNAs, particularly miR-33a and miR-33b, play a significant role in 
regulating cholesterol and fatty acid metabolism [101, 105]. 
In previous studies, Fernández-Hernando´s laboratory and others provided for the first time 
the identification of a miRNA family, miR-33, highly conserved from Drosophila to humans. 
They determined that miR-33 is an intronic miRNA located within the SREBPs gene, key 
transcription factors regulating cholesterol biosynthesis and transport. It was shown that miR-
33 inhibited HDL biogenesis in the liver and cellular cholesterol efflux by targeting multiple 
genes regulating cholesterol homeostasis, including Abca1, Abcg1 and Npc1 [101]. 
Antagonism of miR-33 in vitro and in vivo significantly increased ABCA1 expression, 
promoted cholesterol efflux to Apo-A1 and increased HDL plasma levels in mice [99-104]. 
Furthermore, Fernández-Hernando´s and Gerin´s group identified in 2010 new targets of 
miR-33 involved in fatty acid metabolism including Cpt1a, Crot and Hadhb. Overexpression 
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of miR-33 lead to the accumulation of triglycerides in human hepatic cells and in the fat body 
of miR-33 transgenic flies [105]. Previous work also revealed an interesting role for miR-33 in 
glucose metabolism, as miR-33 overexpression reduced IRS2 levels and inhibited activation 
of downstream messenger cascades, including PI3/Akt pathway [105]. Consistent with these 
findings, miR-33b overexpression reduced insulin-induced 2-deoxyglucose (2-DOG) uptake 
in hepatic cells, suggesting that miR-33 plays a key role in regulating insulin signaling [105]. 
miRNAs represent an elegant layer above transcriptional control for both fine-tuning and 
dramatically altering activity and output of cell signaling. In addition, miRNAs may serve as 
points of crosstalk between signaling pathways by integrating transcriptional inputs or by 
their functional regulatory output on different gene networks. The dysregulation of many 
siRNAs and miRNAs has been linked to the development and progression of disease and, 
consequently, these non-coding RNAs have gained considerable attention as therapeutic 
targets [118]. The results obtained highlight the use of anti-miR-33 therapies in the treatment 
of a number of metabolic disorders, such as dyslipidemias, atherosclerosis, type II diabetes 
and metabolic syndrome. Inhibition of miRNA expression can be achieved using anti sense 
oligonucleotides, termed “antagomirs”, or their chemically modified versions, 2´ O-methyl (2´-
Ome)-oligonucleotides and locked nucleic acid (LNA), termed “anti-miRs”. Additionally, the 
production of the mature forms can also be disrupted at the processing level [119-122]. 
Using anti-miR-33 treatment to elevate ABCA1 levels and increase HDL levels would hold 
tremendous potential for the treatment and/or the prevention of coronary artery disease 
(CAD), in which an underlying risk factor is low levels of HDL. Moreover, inhibition of miR-33 
would result in increased fatty acid oxidation and reduced accumulation of fat stores in the 
liver, suggesting that antagonism of endogenous miR-33 may also be used to treat metabolic 
syndrome and non-alcoholic fatty liver disease (NAFLD). While there are still unanswered 
questions surrounding miRNA therapeutics, the promise demonstrated by the use of anti-
miRs in preclinical studies raised the possibility that miR-33 may become a viable therapeutic 
target in the future [104,105,149]. 
DISCUSSION   65 
4.2 miR-33 is a novel regulator of cell cycle progression and proliferation 
 
This venture led to conclusive mechanistic evidence for miR-33 as a very versatile regulator 
of cell cycle progression, cell proliferation and liver regeneration. The data presented herein 
constitutes the first example of a single miRNA with the ability to influence major pathways of 
metabolism and cell cycle and fills another piece of the puzzle linking lipid synthesis, cell 
cycle, SREBPs and miR-33, hinting a regulatory role for cholesterol in cell cycle progression.  
Since SREBPs have been implicated in the regulation of cell cycle [123], we decided to 
investigate the link between miR-33 and cell cycle progression as well as cell proliferation. 
Using bioinformatics approaches, potential miR-33 binding sites were predicted in genes 
involved in cell cycle progression and cell proliferation. Indeed, the overexpression of miR-33 
in vitro reduced CDK6 and CCND1 at the mRNA and the protein level, consequently 
reducing cell proliferation and notably arresting cell cycle in the G1 phase. Conversely, 
inhibiting miR-33 increased expression of CDK6 and CCND1 and promoted proliferation. 
miR-33 overexpression reduced cell proliferation and retarded cell cycle progression from the 
late G1 into the S phase in human hepatic cells. 
Since we observed that the 3’UTR of human and mouse CCND1 harbors one putative site 
recognized by miR-33, and more importantly, miR-33 and CCND1 expression seemed to be 
inversely correlated in several experiments, we hypothesized that CCND1 may be directly 
regulated by miR-33 at the posttranscriptional level. By a luciferase-based reporter assay, we 
showed that one predicted miR-33 targeting site in the 3´UTR of CCND1 is functional, and 
the expression of miR-33 caused a significant decrease, both at the mRNA and the protein 
level. Comparatively, the same was observed for the CDK6 human and mouse 3´UTR. In this 
case, the 3´UTR of CDK6 harbored three putative sites for miR-33. The same luciferase-
based reporter assay confirmed that the three predicted miR-33 binding sites were 
functional. In particular, the second binding site seemed to be the most important for the 
repression of CDK6, since the 3´UTR activity of CDK6 decreased by 40% when transfected 
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with miR-33 as compared to the control. Similarly, the mRNA and protein levels of CDK6 
decreased significantly when miR-33 was overexpressed.  
Cell cycle progression involves the sequential activation of different cyclin-dependent 
kinases. The expression of cyclins and other regulators of CDKs vary during cell cycle 
progression [32]. CDK6 and CCND1 have been shown to be essential for the regulation of 
cell cycle progression during G1/S phase transition [124]. Our study indicated miR-33 to 
inhibit proliferation and to cause cell cycle arrest at the G1 phase in different cell lines and 
the mechanism involved the downregulation of CCND1 and CDK6 by direct binding of miR-
33.      
In addition to miR-33, many miRNAs have been shown to play a role in regulating 
proliferation and cell cycle progression [125]. The miR-15a-16-1 cluster (miR-15a and miR-
16-1 are transcribed as a cluster residing in the 13q14 chromosomal region) may induce cell 
cycle arrest at the G1 phase by targeting critical cell cycle regulators such as CDK1, CDK2 
and CDK6, as well as their partner cyclins CCND1, CCND2 and CCNE1 [84, 126, 127]. 
Indeed, the major cell cycle kinase complexes are regulated by several other miRNAs. Thus, 
the 3´UTR of CDK6 mRNA is also targeted by miR-24, miR-34a, miR-124, miR-125b, miR-
129, miR-137, miR-195, miR-449 and let7 family members. Likewise, the levels of D-type 
cyclins are downregulated by let-7, miR-15 family, miR-17, miR-19a, miR-20a and miR-34 
[125]. 
A variety of tumor types are associated with inappropriate miRNA expression or structural 
alterations of miRNA genes, demonstrating the oncogenic or tumor-suppressive potential of 
specific miRNAs [128, 129].  Herrera-Merchán et al. in 2010 demonstrated the action of miR-
33 upstream of p53. In fact, they showed how important miRNAs are in tumorigenesis when 
miR-33 can replace p53-loss in the classic oncogenic cooperation assays with oncogenic 
Ras [108]. Although, it is becoming increasingly clear that the majority of the miRNAs target 
multiple genes with related functions and thereby exert strong effects on a particular 
regulatory pathway, the so called fine tuners. As described by the aforementioned group, 
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miR-33 functions to influence tumor-suppressor networks by suppressing p53, essential 
regulators of cell survival [108]. Given that p53 is frequently downregulated in cancers and 
that the p53 gene itself is not mutated, it would be very interesting, from a clinical point of 
view, to investigate whether miR-33-p53 dysregulation represents a novel mechanism for 
cellular transformation in certain types of cancer.   
 
4.3 miR-33 involvement during liver regeneration 
 
This study furthermore showed that in vivo inhibition of miR-33 using antisense 
oligonucleotides improved liver regeneration after partial hepatectomy. The in vitro findings 
were then verified in an in vivo model of liver regeneration induced by a 70% resection of the 
liver. The recovery of the liver function after hepatectomy is promoted by a variety of signals 
that lead to a prompt re-establishment of liver mass by upregulating cell growth and/or 
proliferation [130, 131]. Several proteins involved in regulating cell cycle progression play a 
key role during hepatocyte replication and liver growth [124, 132, 133]. Indeed, transient 
expression of CCND1 is sufficient to promote hepatocyte replication and liver growth in vivo 
[132]. D-and E- type cyclins and their CDK partners CDK4/6 regulate cell cycle progression 
through G1 to S phase [134]. Activation of the CCND1/CDK6 complex phosphorylates and 
inactivates the retinoblastoma protein, a repressor that in turn, inhibits the E2F transcription 
factor and recruits chromatin-remodeling complexes that lead to the repression of specific 
targeted genes.   
In the normal adult liver, hepatocytes are highly differentiated and rarely undergo cell 
division, but they retain a remarkable ability for proliferation in response to an acute or 
chronic injury if necessary [113]. Previous studies have suggested that CCND1 is a critical 
mediator of G1 progression in hepatocytes. Similarly, CDK4/CDK6 regulate cell cycle 
progression in hepatoma cells. Accordingly, Huh7 and HepG2 cells, both human 
hepatocellular liver carcinoma cell lines, treated with PD_0332991, a potent inhibitor of these 
kinases, arrested the cells in the G1 phase [135]. 
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In the present work, it was demonstrated that miR-33 targeted CCND1 and CDK6 and 
consequently regulated hepatocyte proliferation. In addition to CCND1 and CDK6, it has 
previously been reported that miR-33 also targets p53 and Pim-1. p53 activates the 
transcription of genes that induce cell cycle arrest, apoptosis and senescence in response to 
several stress conditions, including DNA damage. In our work, we did not find differences in 
the number of apoptotic cells when miR-33 was overexpressed or inhibited, suggesting that 
the effect of miR-33 on p53 and cell viability may be cell type-specific. On the other hand, 
Thomas M. et al. 2012 have recently shown that miR-33 also targets the serine/threonine-
protein kinase Pim-1 and inhibits proliferation in K562 and LS174T cells [109].   
The overall impact of miRNAs on liver regeneration has been studied by generating mice 
with hepatocyte-specific miRNA deficiency [136]. Song et al. addressed this question by 2/3 
partial hepatectomy (PH) on mice with hepatocyte-specific inactivation of DiGeorge 
syndrome critical region gene 8 (DGCR8), an essential component of the miRNA processing 
pathway. These mice were viable and developed normally until adulthood. However, 
whereas miRNA-deficient hepatocytes readily exited the G0 phase of the cell cycle, they 
failed transition into the S phase by 36h after PH, suggesting a key role of miRNA in 
regulating liver regeneration. Examination of livers of wildtype mice after 2/3 PH revealed 
differential expression of a subset of miRNAs, notably an induction of miR-21 and repression 
of miR-378. It was further discovered that miR-21 directly inhibited Btg2, a cell cycle inhibitor 
that prevents activation of forkhead box M1 (FoxM1), which is essential for DNA synthesis in 
hepatocytes after 2/3 PH. In addition, miR-378 was found to directly inhibit ornithine 
decarboxylase (Odc1), which is known to promote DNA synthesis in hepatocytes after 2/3 
PH [137]. 
The whole process of liver regeneration has three clearly distinct phases: an initiation stage, 
a proliferation stage and a termination stage [138]. Most research has focused on the first 
two stages. However, the participants at the stage of termination have not been well 
characterized so far. Most of the studies have focused on the anti proliferative role of 
transforming growth factor (TGF)-β1 [130]. However, the fact that transgenic mice displayed 
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a complete, although delayed, liver regeneration suggests that other mediators must be 
involved in this process [139]. In this context, our results support the idea that miR-33 may 
have a significant role in mediating the termination signal in the process of liver regeneration. 
These new findings could open new therapeutic perspectives to stimulate liver regeneration 
in chronic liver disease or after liver resection in patients affected by hepatocellular 
carcinoma.   
 
4.4 miR-33: one miRNA, many targets  
 
Currently, an important question in the miRNA field is whether these small regulatory 
molecules achieve their physiological impact through repression of a single or a few cardinal 
targets, or via the cumulative impact of impairing the expression of large sets of targets [145]. 
Whereas most experimental evidence supports the latter option, there are some reported 
cases where siRNA-mediated downregulation of one single gene resembled miRNA-
mediated phenotypes. Namely, a specific knockdown of phosphatidylinositol-3,4,5-
trisphosphate 5-phosphatase 1 (SHIP1) in the murine hematopoietic system following 
retroviral delivery of a miR-155-formatted siRNA against SHIP1 resulted in a 
myeloproliferative disorder, with striking similarities to the one observed in miRNA-155 
overexpressing mice [146]. According to the data presented here, two critical cell cycle 
progression genes, whose expression is impaired simultaneously and directly by miR-33, 
could be identified. Importantly, as determined by gene-specific knockdown experiments, 
Cdk6 gene was not capable by itself of phenocopying the liver regeneration effect of anti-
miR-33 treatment in its whole magnitude. This supports the idea that the effect mediated by 
miR-33 is rather the consequence of a multiple synergistic small changes in the expression 
levels of various genes, than being attributable to the impaired expression of one single 
master gene.    
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4.5 Conditional miR-33 knockout  
 
To understand the physiological role of miR-33 in vivo, a miR-33 conditional deficient mouse 
model was generated. Typically Cre-loxP mice are produced by using transgenic technology 
[140-142]. We used the Cre-loxP and the FLP-FRT systems as a genetic tool to enable cell 
type specific and/or inducible deletion of miR-33. The loxP and the FRT sites were placed in 
cis (same DNA strand) and the same directional orientation. This is a common approach, 
which results in a simple excision of the flanked element (Fig. 24). There are several 
advantages using this technique. First, in comparison to shRNA or siRNA experiments, the 
floxed gene or element will be completely deleted. Second, the model will provide an in vivo 
system spatial and temporally specific. Many mice carrying a Cre recombinase under the 
control of a tissue-specific promoter can be used to knock out the miR-33 in a “guided” 
manner. For example, albumin-Cre mice [143] will be crossed with miR-33flox/flox to enable 
access to a liver-specific miR-33 knock-out. Moreover, it facilitates the construction of a 
variety of Cre-mediated mouse models and Cre-inducible mice. This approach allowed us to 
study the effect of miR-33 in various and different tissues and models, in vitro and in vivo.  
The targeting vector was constructed to flank the miR-33 genomic coding region (76bp) in 
intron 17 of the Srebf2 gene with loxP recombination sites and to insert a neomycin selection 
cassette flanked by FRT sites (Fig. 24). We obtained chimeras and the mutated allele was 
successfully transmitted into the germ line. The selection cassette from the conditional allele 
was removed in vivo, with FLP-deleter mice as shown in Fig. 24 [115, 116]. The sequence of 
the floxed miR-33 allele was confirmed by PCR-screening. miR-33flox/flox animals were fertile 
and appeared phenotypically normal. This suggests that the integrated loxP sites did not 
interfere with miR-33 transcription.  Deletion of the floxed miR-33 genomic coding region was 
achieved with Cre-recombinase in vivo and in vitro. This Cre-mediated excision resulted in a 
complete loss of function of miR-33. No functional miR-33 was produced and this lead to a 
complete null phenotype. miR-33 was first deleted in vivo by crossing miR-33flox/flox mice with 
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an early Cre-expressing deleter EIIa-Cre strain [144]. This line carried a Cre transgene under 
the control of the adenovirus EIIa promoter that targets expression of Cre recombinase to the 
early mouse embryo. Cre expression is thought to occur prior implantation in the uterine wall. 
The deletion of miR-33 by the Cre-recombinase resulted in no phenotype.  
 
4.6 Concluding remarks and outlook 
 
Our data suggests a model in which miR-33a and miR-33b work in concert with their host 
genes Srebf-2 and Srebf-1, respectively, to ensure a balanced metabolic state in the cell. 
During low cholesterol conditions miR-33a and miR-33b coexpressed with their host genes 
boost intracellular cholesterol levels by targeting ABCA1, reduce insulin signaling by 
targeting IRS2, and increase fatty acid levels by targeting a variety of fatty acid oxidation 
enzymes. Given that the abnormal regulation of these pathways leads to diseases such as 
atherosclerosis, metabolic syndrome and NAFLD, miR-33 could then represent an ideal 
target for future therapies [107].  
In particular, the development of novel therapies to exploit the atheroprotective properties of 
HDL is an area of intense investigation. In randomized clinical trials raising plasma HDL by 
augmenting ApoA-1 levels or treating with niacin have shown direct benefits in patients with 
coronary artery disease, including reduced cardiovascular event rates and plaque volume 
[147, 148]. Previous studies have shown that inhibition of miR-33a in mice is an effective 
strategy to raise plasma HDL [99-101], and to enhance reverse cholesterol transport and 
regress atherosclerotic plaques [104]. Although promising, these studies in mice are limited 
in their translational insight due to the lack of miR-33b expression, which may contribute 
substantially to miR-33 levels in humans. Rayner et al. recently published in Nature a study 
regarding this feature, showing for the first time in non-human primates that inhibiting both, 
miR-33a and miR-33b, has a profound and sustained effect on circulating plasma HDL levels 
[149]. Importantly, this study also established that miR-33 antagonism markedly suppresses 
plasma VLDL triglyceride levels, in part attributable to the regulation of key genes involved in 
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fatty acid oxidation and synthesis [103, 105]. As low HDL and high VLDL triglycerides are 
commonly associated with metabolic syndrome [150], miR-33 inhibitors may have clinical 
utility for the treatment of this growing health concern. These findings in non-human primates 
support the development of antagonists of miR-33 as potential therapeutics for dyslipidemia, 
atherosclerosis, and related metabolic diseases. 
Furthermore, our results revealed that the decreased expression of miR-33 during liver 
regeneration causes proliferation in hepatocytes. This raises the possibility of using anti-
oligonucleotides of miR-33 for therapy in liver failure. They may be effective in accelerating 
progression of hepatocytes through G1 and into S phase, which is critical for survival after 
liver injury [151]. 
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